| Company (Country/ Symbol) | Company (Country/ Symbol) | Type/ Product Area | Terms/Details (Month) |
| Abgenix Inc. (ABGX) | Gliatech Inc. (GLIA) | License and option agreement/use of Abgenix s XenoMouse technology to generate fully human monoclonal antibodies to the complement protein properdin for use in the fields of cardiovascular and inflammatory diseases | Abgenix will receive a technology an access payment and could receive additional fees and milestones, plus royalties on product sales; Gliatech will be responsible for development, manufacturing and marketing (1/00) |
| Abgenix Inc. (ABGX) | Neuralab Ltd. (unit of Elan Corp. plc; Ireland; NYSE:ELN) | License and option agreement/use of Abgenix s XenoMouse technology to generate fully human monoclonal antibodies to an undisclosed antigen in the field of neurological diseases | Abgenix will receive a technology access payment and could receive additional fees and milestones, plus royalties on product sales; Elan will be responsible for development, manufacturing and marketing (1/00) |
| Abgenix Inc. (ABGX) | Corixa Corp. (CRXA) | Research collaboration/use of Abgenix s XenoMouse develop technology to dis cover monoclonal antibodies against selected targets from Corixa s library of autoimmune disease, cancer and infectious disease targets | Six-year agreement covers three initial targets and up to six per year; each antibody eligible for clinical testing will be subject to a closed auction between the two companies for rights to development; the winning company will pay the bid amount in cash to the other company and will be responsible for all development expenses and decisions; the non-development company will receive a share of future product development milestones and a small royalty on any sales (3/00) |
| Abgenix Inc. (ABGX) | Immunex Corp. (IMNX) | Development and commercialization agreement/Abgenix s ABX-EGF, an anti cancer monoclonal antibody to the receptor for epidermal growth factor | Immunex will make an initial license fee payment to Abgenix and a second payment upon commencement of Phase II clinical trials; development costs will be shared equally, as would any potential profits from sales of a targeted product; responsibility for product development will be shared by both companies; Abgenix will complete the ongoing Phase I trial, while both companies will share efforts in the execution of Phase II trials; Immunex will have primary responsibility for Phase III clinical trials and will market any potential product, while Abgenix will retain co-promotion rights (7/00) |
| Abgenix Inc. (ABGX) | Lexicon Genetics Inc. (LEXG) | Research collaboration/use of Abgenix s XenoMouse technology to discover antibodies to Lexicon s genomic targets | Each company will have the right to obtain exclusive commercialization rights, including sublicensing rights, for an equal number of promising antibodies; each will receive milestones and royalties on sales of antibody drugs from the collaboration that are commercialized by the other party or through a third-party collaboration (7/00) |
| Abgenix Inc. (ABGX) | SangStat Medical Corp. (SANG) | Global co-development supply and license agreement for ABX-CBL | SangStat will have an exclusive worldwide license for the marketing and sale of ABX-CBL and, subject to terms and conditions, the right to commercialize other anti-CD147 antibodies; Abgenix will manufacture ABX-CBL; SangStat will make an initial license fee payment and additional milestone payments; development costs and potential profits will be shared equally (8/00) |
| Abgenix Inc. (ABGX) | CuraGen Corp. (CRGN) | Strategic alliance expanded to develop and test up to 250 fully human antibody therapeutic candidates using XenoMouse and functional genomics technologies | Original agreement was for 120 candidates to treat metabolic diseases, cancer, inflammation and autoimmune disorders; Abgenix will make an equity investment in CuraGen totaling $50M; each company expects to invest an additional $100M in support of the collaboration (11/00) |
| Abgenix Inc. (ABGX) | Immunex Corp. (IMNX) | Multiyear collaboration to discover, develop and commercialize fully human monoclonal antibodies to treat cancer | Each company will contribute five cancer-specific antigen targets during the first five years, sharing their technologies; the companies will share equally in development and commercialization of any product (11/00) |
| Acadia Pharmaceuticals Inc. | ArQule Inc. (ARQL) | License/serotonergic lead compounds discovered in companies ongoing research collaboration | Acadia will obtain rights to develop and commercialize drugs based on novel leads and will pay ArQule milestones and royalties; companies will continue their pre-existing research collaboration on several other gene-derived targets (5/00) |
| Acadia Pharmaceuticals Inc. | Allergan Inc. (NYSE:AGN) | Extension of functional genomics collaboration formed in September 1997 | Acadia and Allergan extended their collaboration for two years to study AGN 195795 for glaucoma in the clinic (10/00) |
| Access Pharmaceuticals Inc. (AMEX:AKC) | Laboratorios Dr. Esteve SA and Isdin SA (Spain) | Licensing agreement for OraRinse, amlexanox cream and amlexanox gel | Access signed letters of intent to exclusively license the products to Esteve and Isdin for Portugal, Spain and Greece; Esteve and Isdin will make up-front licensing payments and milestone payments and Access will receive a percentage of product sales for supplying the product; Esteve will make an equity investment in Access and provide funding for European clinical research (8/00) |
| Aclara BioSciences Inc. (ACLA) | Zeptosens AG (Switzerland) | Exclusive license agreement for access to microfluidics intellectual property | Financial terms were ND (11/00) |
| Actelion Ltd. (Switzerland) | Genentech Inc. (NYSE:DNA) | Development and marketing/Tezosentan; endothelin receptor antagonist | The companies will co-promote tezosentan upon FDA approval; Actelion will lead the development effort, while Genentech will lead commercialization; Genentech will pay Actelion an up-front fee of $15M along with additional milestone payments; Genentech will make an equity investment in Actelion s upcoming initial public offering (2/00) |
| Adherex Technologies Inc. (Canada) | BioChem Pharma Inc. (Canada; BCHE) | Collaboration to develop Exherin, Adherex s new compound for cancer | Both companies will participate in research and development activities; BioChem may pay Adherex up to US$25.5M in the form of milestone payments and an equity stake, in addition to sales revenues (8/00) |
| AeroGen Inc. | PathoGenesis Corp. (PGNS) | Research collaboration/use of PathoGenesis FDAapproved TOBI (tobramycin solution for inhalation) and AeroGen s handheld, portable AeroDose Inhaler; goal is to reduce drug s delivery time from 15-20 minutes to 5-10 minutes or less | Under a development and supply agreement, PathoGenesis will reimburse AeroGen for costs incurred in developing the inhaler and will obtain worldwide exclusive distribution rights; AeroGen will receive royalties on all sales; under a separate agreement, PathoGenesis will invest $2.5M in AeroGen s convertible preferred stock (3/00) |
| Aeson Therapeutics Inc. | Hollis-Eden Pharmaceuticals Inc. (HEPH) | Exclusive worldwide sublicense to three additional issued patents in the area of adrenal steroids | Hollis-Eden is exchanging $2M in cash and 208,681 shares for a 21% equity interest in Aeson (10/00) |
| Affymetrix Inc. (AFFX) | NEN Life Science Products | License agreement/lowand medium-density DNA arrays | NEN has been granted a nonexclusive, worldwide, royalty-bearing license allowing it to manufacture, use and sell lowand medium-density pre-spotted arrays; the license applies only to the research field for gene expression analysis and comparative genomic hybridization with mechanically spotted arrays; Affymetrix will receive undisclosed fees and royalty payments on products sold by NEN; NEN will cooperatively promote Affymetrix scanners and software (3/00) |
| Affymetrix Inc. (AFFX) | InphoGene BioCom Inc. | Development collaboration/InphoGene will use Affymetrix s GeneChip probe arrays to build an Internet-based commercial reference source for gene expression information relating to cardiopulmonary disease | InphoGene will market the databases to pharmaceutical and biotechnology companies for use alone or in combination with GeneChip probe arrays or any products compliant with the standards of the Genetic Analysis Technology Consortium; InphoGene will pay Affymetrix annual subcription fees; purchase probe arrays, related instrumentation and software; and, after certain milestones have been achieved, pay royalties to Affymetrix on subscription fees (4/00) |
| Affymetrix Inc. (AFFX) | Gene Logic Inc. (GLGC) | Technology access/Affymetrix to develop a set of custom Gene Chip DNA arrays using Gene Logic s sequence information | Gene Logic will use the arrays to expand its GeneExpress database (5/00) |
| Affymetrix Inc. (AFFX) | MWG-Biotech AG (Germany; Neuer Markt:NWU) | License/certain Affymetrix intellectual property for commercializing lowand medium-density DNA arrays | MWG-Biotech has been granted a nonexclusive, worldwide, royalty-bearing license allowing the company to manufacture, use and sell lowand medium-density pre-spotted arrays; the license provides rights for the research field for gene expression with mechanically spotted arrays; Affymetrix will receive undisclosed fees and royalty payments on products sold by MWGBiotech; MWG-Biotech will cooperatively promote Affymetrix s scanner and software (6/00) |
| Affymetrix Inc. (AFFX) | Deltagen Inc. (DGEN) | Research collaboration/use of Affymetrix s GeneChip probe arrays to build and commercialize Delta Xpress databases of gene expression information based on Deltagen s knockout mouse models | Deltagen will pay annual subscription fees, pay for probe arrays and related instrumentation and software, and pay royalties to Affymetrix on database subscription fees (7/00) |
| Affymetrix Inc. (AFFX) | deCODE genetics Inc. (Iceland; DCGN) | Agreement for BiotechAccess program | deCODE will gain broad access to Affymetrix s standard GeneChip arrays, instrumentation and software to monitor gene expression (8/00) |
| Agilent Technologies Inc. (NYSE:A) | DiaDexus Inc. | Agreement for gene expression system technology | Agreement will allow diaDexus to obtain access to Agilent s customizable microarray technology for research into the molecular basis for cancer and other diseases; financial details were ND (10/00) |
| Agilent Technologies Inc. (NYSE:A) | Exelixis Inc. (EXEL) | Supply agreement for customizable DNA microarrays | Agilent agreed to supply customizable DNA microarrays to Exelixis, which will use the platform for expression profiling experiments; financial details were ND(10/00) |
| Agilent Technologies Inc. (NYSE:A) | Paradigm Genetics Inc. (PDGM) | Technology access program agreement | Agreement will grant Paradigm early access to Agilent s customizable microarray technology; financial details were ND (10/00) |
| Alchemia Pty. Ltd. (Australia) | Dow Chemical Co. (NYSE:DOW) | Joint venture to make complex carbohydrates in commercial quantities for clinical use or biotechnology research | Alchemia will receive an up-front payment plus milestone payments, as well as half of all profits (12/00**) |
| Alkermes Inc. (ALKS) | Amylin Pharmaceuticals Inc. (AMLN) | Research and development collaboration/injectable, longacting formulation of Amylin s AC2993 (synthetic exendin-4) using Alkermes Medisorb delivery technology | Alkermes granted an exclusive, worldwide license for the development of injectable, sustained-release formulations of exendins, such as AC2993, and other related compounds that Amylin may develop; Alkermes will receive funding for research and development, milestones comprised of cash and warrants for Amylin common stock, and royalties and manufacturing fees for commercialized products (5/00) |
| Alkermes Inc. (ALKS) | MedImmune Inc. (MEDI) | Development agreement/development of an inhalable formulation of a monoclonal antibody targeting the respiratory syncytial virus (RSV) using Alkermes AIR pulmonary technology | MedImmune will receive an exclusive, worldwide license to products produced by the collaboration; Alkermes will receive certain initial fees, development funding, milestone payments, manufacturing fees and royalties on product sales; Alkermes is responible for product formulation, pulmonary delivery device development and commercial supply; MedImmune is responsible for clinical development, bulk product supply, regulatory approval and worldwide marketing (6/00) |
| Allergan Inc. (NYSE:AGN) | Dura Pharmaceuticals Inc. (DURA) | Commercialization/selected Allergan products in the U.S. primary care and respiratory segments | The companies entered a multiyear, multiproduct agreement under which they will co-launch Alocril, Allergan s proprietary topical compound for the treatment of itch associated with allergic conjunctivitis; Allergan will promote Alocril to ophthalmologists, and Dura will promote it to primary care practitioners and respiratory specialists; includes a joint structure to evaluate additional opportunities for Dura to promote specific development-stage products, once they receive approval, and a commitment to launch a second product to the same segments on an unspecified date (2/00) |
| Amarillo Biosciences Inc. (OTC BB:AMAR) | Biopharm Group International (Egypt) | Development and marketing/Amarillo s low-dose orally administered interferon-a in conjunction with an antiviral for treatment of hepatitis C | Agreement calls for clinical co-development and marketing (5/00) |
| Amarillo Biosciences Inc. (OTC BB:AMAR) | Key Oncologics Pty. Ltd. (South Africa) | Marketing/Amarillo s low-dose, orally available interferon-a | Agreement provides Key with marketing rights in South Africa, Zimbabwe, Botswana and Namibia (5/00) |
| Amarillo Biosciences Inc. (OTC BB:AMAR) | Hayashibara Biochemical Laboratories (Japan) | Expansion of development agreement/HBL s natural human interferon-g | Expansion is to include worldwide rights for an inhalable dosage form (excluding Japan); Amarillo holds the worldwide development and distribution rights for HBL s interferon-g when used for lowdose oral administration (6/00) |
| Amarin Corp. plc (UK; AMRN) | Laxdale Ltd. | License/LAX-101 to treat Huntington s disease | Agreement includes an up-front payment in cash and stock to Laxdale, future milestone payments and royalties (11/00) |
| AMBI Inc. (AMBI) | Biosynexus Inc. | License/Rights to nisin and lysostaphin antibacterial technologies | Biosynexus will pay AMBI $1.4M up front, up to $14M in milestones, royalties on potential sales, and will grant warrants for the purchase of Biosynexus shares (8/00) |
| American Biogenetic Sciences Inc. (OTC BB:MABA) | Trevigen Inc. | Research collaboration/use of ABS antigen-free technology to produce monoclonal anti bodies for control of DNA damage | ABS will receive a royalty on all commercial products developed from the collaboration and will retain manufacturing rights (5/00) |
| Amersham Pharmacia Biotech (UK; owned by Nycomed; NYSE:NYE; and Pharmacia Corp.; NYSE:PHA) | Analytica of Branford | Marketing/mass spectrometry systems for protein analysis | The companies will collaborate in the development of new, leading-edge systems for the characterization of proteins and peptides; the terms of the agreement are for exclusive distribution and manufacturing of the systems by Amersham; Amersham intends to acquire a majority stake in Analytica (3/00) |
| Amersham Pharmacia Biotech (UK; owned by Nycomed; NYSE:NYE; and Pharmacia Corp.; NYSE:PHA) | BioImage A/S (Denmark) | Collaboration to commercialize a new cell-based screening technology based on green fluorescent protein | Amersham Pharmacia gains an exclusive license to BioImage s European patent portfolio on GFP, including the right to sublicense the technology (12/00) |
| Amgen Inc. (AMGN) | HealthCite | Strategic partnership to collaborate on software, technology and web development opportunities | Terms include a $10M direct investment by Amgen in HealthCite (8/00) |
| Amgen Inc. (AMGN) | Oxford Asymmetry International plc (UK; unit of Evotec Biosystems AG; Neuer Markt:EVT) | Collaborative agreement for OAI chemists to provide Amgen with discovery chemistry services | The 1.8M (US$2.6M) agreement includes fees for services and future milestone payments (12/00) |
| Amphioxus Cell Technologies Inc. | Incyte Genomics Inc. (INCY) | License agreement/Amphioxus C3A cloned human liver cell line for the creation of geneexpression databases | Incyte gains exclusive access to the cell line for creation of gene-expression databases; companies also have a co-marketing arrangement for distribution and licensing of the cell line (1/00) |
| Amrad Corp. Ltd. (Australia; ASX:AML) | DevCo Pharmaceuticals Ltd. (UK) | License agreement/Amrad s AM36 compound as a treatment for stroke | DevCo will design, carry out and fund the development program up to and including proof-ofprinciple Phase II studies, at which point Amrad has the right of first refusal to either buy back worldwide rights or share in commercial proceeds; Amrad retains rights to market the drug in Australia and New Zealand (3/00) |
| Amylin Pharmaceuticals Inc. (AMLN) | Alkermes Inc. (ALKS) | Completion of the feasibility stage of a collaboration for the development of an injectable long-acting-release formulation of AC2993 | Amylin and Alkermes completed the feasibility stage of the collaboration and additional preclinical work has begun to support AC2993 as a treatment for Type II diabetes; Alkermes received a milestone payment (10/00) |
| AndroSolutions Inc. | Vivus Inc. (VVUS) | Joint venture/intellectual property related to female sexual dysfunction | Companies formed Asivi LLC, in which Vivus placed its U.S. female sexual dysfunction patent and European application, and AndroSolutions placed its U.S. and European applications; Asivi gives Vivus exclusive worldwide rights to commercialize the technologies in return for milestones and royalties (3/00) |
| AngioSense Inc. | Repair Inc. | Joint collaboration to pursue clinical applications for sustained delivery of fibroblast growth factor to simulate growth of new blood vessels in diseased hearts | AngioSense will supply its needle-free, jet-injection delivery system and Repair will provide FGF protein and fibrinogen constructs; financial details were ND (10/00) |
| Antex Biologics Inc. (AMEX:ANX) | Lyotropic Therapeutics LLC | Collaboration to formulate Antex s antibiotic candidates with Lyotropic s LyoCell drug delivery system | The preclinical drug candidates are being developed to treat serious infections caused by vancomycin-resistant Enterococci, methicillin-resistant Staphylococcus aureus and other organisms (9/00) |
| AnVil Informatics Inc. | PolyGenyx Inc. | Collaboration on bioinformatics projects | Companies will work jointly on projects related to PolyGenyx s SNP genotyping and haplotyping programs; AnVil will build a database suitable for hosting data from PolyGenyx s laboratory; companies also are in discussion for a longer-term collaboration on data exploration projects (9/00) |
| Applied Molecular Evolution Inc. (AMEV) | Bio-Management Inc. | Development/DirectAME directed evolution technology for the development of antibodies for therapeutic and diagnostic applications | BMI will fund research covering two to four antibodies, as well as make milestone payments of up to $17M; AME also will receive royalties on marketed products developed with its DirectAME technology (2/00) |
| Applied Molecular Evolution Inc. (AMEV) | IDEXX Laboratories Inc. (IDXX) | Nonexclusive sublicense to Applied Molecular s Kauffman patents for directed evolution | Applied Molecular granted a nonexclusive sublicense to IDEXX, which will use the patents to develop diagnostic applications; the patents cover methods of stochastically generating proteins (9/00) |
| Applied Molecular Evolution Inc. (AMEV) | Biosynexus Inc. | Collaboration to develop an optimized prophylactic agent for staphylococcus bacterial infection in neonatal and pediatric populations | AME will receive research and development funding, milestone payments and royalties (12/00) |
| Aquila Biopharmaceuticals Inc. (AQLA) | Neuralab Ltd. (unit of Elan Corp. plc; Ireland; NYSE:ELN) | License agreement/use of Aquila s Stimulon adjuvant QS-21 with an undisclosed antigen in the field of Alzheimer s disease | Aquila received a license payment and could receive additional fees and milestones plus royalties on product sales; Elan will be responsible for product development and marketing; companies also signed a supply agreement for the adjuvant (1/00) |
| Arakis Ltd. (UK) | Vectura Ltd. | Collaboration/develop an inhaled formulation for AD237 to treat chronic pulmonary disease | Companies will share development costs and revenues (11/00) |
| Arena Pharmaceuticals Inc. (ARNA) | Lexicon Genetics Inc. (LEXG) | Research collaboration/dis covery of drug candidates that target G protein-coupled receptors | Both companies will contribute equal numbers of GPCRs to be validated simultaneously by Lexicon s Seek Target Validation Program and and Arena s CART technology; each will share equally in up-front fees, milestones and royalties from products developed from alliance GPCRs and will fund its own effort; the companies plan to partner the majority of candidates with third parties (8/00) |
| Argonaut Technologies Inc. (AGNT) | MediChem Research Inc. | Development collaboration/methodology to speed chemical reaction optimization; methodology will combine parallel synthetic methods with statistical Design of Experiments software using MediChem s technology | Argonaut will incorporate the methodology with its existing Surveyor instrument and will distribute the integrated platform worldwide (7/00) |
| Ariad Pharmaceuticals Inc. (ARIA) | NsGene A/S (Denmark) | Collaboration to evaluate smallmolecule-regulated gene and cell therapy products for central nervous system diseases | Companies will combine the Ariad Regulated Gene Expression Technology with NsGene s neurotrophic factors and technologies for culturing and engineering neural cells; development and commercial terms will be determined following the initial research phase of the collaboration (9/00) |
| ArQule Inc. (ARQL) | Nanoscale Combinatorial Synthesis Inc. | Microchemistry technology evaluation and chemistry services agreement | Nanosyn will perform custom chemical synthesis projects enabling ArQule to evaluate Nanosyn s Accelerated Nanoscale Synthesis Technology System; ArQule will provide funding for a period of up to two years; financial terms were ND (8/00) |
| ArQule Inc. (ARQL) | Genome Therapeutics Corp. (GENE) | Drug discovery collaboration for anti-infective targets | Arqule will use Parallel Track Drug Discovery program to screen and optimize anti-infective compounds, which Genome derived from its PathoGenome Database; the agreement replaces the 1998 collaboration and includes increased commitment of resources from both companies and joint ownership rights to all lead compounds and commercial outcomes (10/00) |
| ArQule Inc. (ARQL) | Acadia Pharmaceuticals Inc. | Drug discovery collaboration to to discover novel small-molecule drug candidates directed at individual G protein-coupled receptor targets | Companies will share intellectual property resulting from the collaboration and will equally contribute to at least one joint drug discovery program; they also will share revenues resulting from commercialization of any products (12/00) |
| Array Biopharma Inc. (ARRY) | Tularik Inc. (TLRK) | Research collaboration/Array will design and synthesize a small-molecule-focused library targeting orphan nuclear receptors discovered by Tularik | Following a period of exclusivity with Tularik, Array may offer the compounds in the library to third parties (5/00) |
| Array Biopharma Inc. (ARRY) | ICOS Corp. (ICOS) | Expansion of research collaboration/expansion based on discovery of a clinical candidate inhibitor of PDE4 | Companies entered a process and manufacturing agreement and have expanded their initial drug discovery collaboration, which focused on lead optimization for four ICOS targets (8/00) |
| Array BioPharma Inc. (ARRY) | Immunex Corp. (IMNX) | Multiyear agreement providing access to smallmolecule libraries | Array will provide Immunex with access to smallmolecule libraries for screening against Immunex s high-throughput screening assays; Immunex will gain access to the libraries on a nonexclusive basis; Array retains an exclusive option to enter into a lead-optimization agreement with Immunex to develop leads generated; financial terms were ND (10/00) |
| Array BioPharma Inc. (ARRY) | Amgen Inc. (AMGN) | Research and license agreement to identify and optimize smallmolecule inhibitors | Companies will collaborate to optimize smallmolecule inhibitors to the phosphatase target, PTPIB, to treat diabetes and related diseases; Array will provide Amgen with an exclusive license to Array s existing PTBIB program and exclusive worldwide rights to develop and commercialize PTPIB-related products (11/00) |
| Arrow Therapeutics Ltd. (UK) | Triangle Pharmaceuticals Inc. (VIRS) | Development agreement/development of novel antiviral agents | Arrow will contribute the target, highthroughput screening (HTS) technology and compound library; Triangle will contribute preclinical and clinical development experttise; Triangle will cover up-front research funding and will make contingent development milestone payments as well as paying royalties on sales (7/00) |
| Arrow Therapeutics Ltd. (UK) | Virogen Ltd. (UK) | Discovery and development agreement for respiratory syncytial virus therapies | Each company will fund its own research and will share revenues generated (12/00) |
| Athersys Inc. | Elan Corp. plc (Ireland; NYSE:ELN) | Development and marketing/undisclosed therapeutic protein for the treatment of AIDSassociated muscle wasting | The companies will combine Athersys RAGE (Random Activation of Gene Expression) technology with Elan s Medipad drug delivery system; Elan has made a significant equity investment in Athersys; further details were ND (2/00) |
| Athersys Inc. | Molecumetics Ltd. (unit of Tredegar Corp.; NYSE:TG) | Development collaboration for small-molecule drugs | Athersys will use its RAGE-VT technology to provide Molecumetics with 12 cell lines expressing validated targets of interest; Molecumetics can access the targets by paying a licensing fee or through a co-development option allowing both companies to co-invest in particular projects and share in downstream value (10/00) |
| Atrix Laboratories Inc. (ATRX) | Elan Corp. plc (Ireland; NYSE:ELN) | Joint venture/development of oncology and pain management products using Atrix s BEMA and Atrigel systems and Elan s NanoCrystal technology | Elan will provide development funding, but Atrix initially will be the majority owner of the venture; Elan will make an equity investment of $5M in Atrix at a premium (6/00) |
| atugen AG (Germany) | GPC Biotech AG (Germany; Neuer Markt:GPC) | Technology alliance/companies will combine technologies to create a fully integrated functional genomics and proteomics platform | Companies will offer combined platform to third parties for target discovery and validation (2/00) |
| atugen AG (Germany) | Axys Pharmaceuticals Inc. (AXPH) | Research collaboration/gene target validation services through atugen s U.S. subsidiary | Axys will provide atugen with gene targets in oncology, and atugen will develop GeneBloc reagents to knock down the genes of interest to evaluate gene function and potential as therapeutic drug targets; atugen will perform quantitative RNA analysis and technology transfer to enable Axys to use the best GeneBlocs; financial details ND (3/00) |
| Aurora Biosciences Corp. (ABSC) | Rigel Inc. (RIGL) | Reciprocal technology access/Aurora s green fluorescent protein technology and Rigel s retroviral and peptide selection technologies | Rigel gains a nonexclusive license to use the GFP technology in certain areas related to gene analysis; Aurora will receive an up-front payment, annual fees and equity in Rigel; Rigel will permit Aurora to access combinatorial screening technology for target identification and validation; both companies can perform services for third parties in exchange for royalties on services and downstream revenues (2/00) |
| Aurora Biosciences Corp. (ABSC) | Senomyx Inc. | Exclusive collaborative research and license agreement for the discovery of consumer products enhancing taste and olfaction | Employ green fluorescent protein technology and beta-lactamase technology to develop screening platforms for Senomyx and conduct high-throughput screening; agreement includes an up-front technology access fee, research funding and performance milestones; Aurora purchased 1M shares of Senomyx s Series C preferred stock for $4.8M (11/00) |
| AutoImmune Inc. (AIMM) | Subsidiary of Elan Corp. plc (Ireland; NYSE: ELN) | License/AutoImmune s rights to patent applications involving the treatment of Alzheimer s disease | AutoImmune will receive up to $7M in cash in a combination of up-front payments and contingent payments over the next three years; at the time the contingent payments are made, the buyer will receive warrants to purchase up to 0.75M shares of AutoImmune stock at the market price when the warrants were issued (3/00) |
| AutoImmune Inc. (AIMM) | Rycor Technology Investments Corp. | Exclusive license for AutoImmune s methods to treat autoimmune diseases | The license agreement covers the development by Rycor of native myelin basic protein peptides for injection to nonmucosal sites for the treatment of multiple sclerosis (8/00) |
| AVI BioPharma (AVII) | Gene Tools LLC | License to in vitro diagnostic applications of AVI s Neugene antisense technology | AVI received $1M and additional undisclosed consideration from Gene Tools in exchange for an exclusive license (the companies previous agreement was nonexclusive) (3/00) |
| AVI BioPharma (AVII) | SuperGen Inc. (SUPG) | Sales and marketing/AVI s therapeutic cancer vaccine, Avicine | SuperGen will make an up-front equity investment of $20M in a combination of cash and SuperGen stock; additional equity investments and milestone payments are contemplated that would make the total value of the pact in excess of $100M; SuperGen also will receive a warrant to purchase an additional 10% of AVI stock at a 300% premium to the 4/4/00 closing price of $35.625 per share; the companies will share profits and development/regulatory costs in the U.S.; SuperGen will be responsible for U.S. marketing and sales, and AVI will be responsible for manufacturing; companies will jointly determine development strategy for the international marketplace and share all profits; SuperGen paid $5M in 12/99 for the right to negotiate a marketing deal (4/00) |
| AVI BioPharma (AVII) | Interventional Technologies | Clinical trial collaboration/AVI s Resten-NG, a gene targeted therapeutic for cardiovascular restenosis | IVT will supply its Infiltrator intramural delivery catheters for upcoming Phase II trials; AVI will use the catheter in its Resten-NG development program; further details were ND (3/00) |
| Avigen Inc. (AVGN) | BTG International Ltd. (unit of BTG plc; UK; LSE:BGC) | License/Factor IX gene patents | Avigen obtained a nonexclusive, worldwide license to Factor IX gene patents; Avigen has the right to make, use, sell, offer for sale, or import viral vector systems, including adenoassociated virus, using the Factor IX gene for in vivo human gene therapy; Avigen also has the right to sublicense the patents to third parties; financial details were ND (3/00) |
| Avigen Inc. (AVGN) | Stratagene | License/Stratagene granted worldwide exclusive rights | Avigen will receive an up-front payment and royalti |
| Biogen Inc. (BGEN) | NsGene A/S (Denmark) | Option license exercised for Neublastin | Biogen will pay an up-front fee for the license and will pay NsGene $20M in fees and milestone payments upon commercialization of the neurodegenerative disease therapeutic (12/00) |
| Biohybrid Inc. | TKB Associates | Access/CD8-mediated veto | Biohybrid purchased the patent rights to CD8mediated veto from TKB; TKB will receive an equity position in the company, as well as royalty and milestone payments; further details were ND (3/00) |
| Bioject Medical Technologies Inc. (BJCT) | Amgen Inc. (AMGN) | Development collaboration/use of Bioject s needle-free jet-injection system to deliver Amgen products | Amgen will invest $1.5M in Bioject s common stock and up to $3.1M in future milestones, fees and development support; Amgen receives an exclusive license to the technology for delivery of Amgen products for two indications; Amgen also gains option to further license the technology for other Amgen products; agreement outlines a future commercial supply agreement (3/00) |
| Bioject Medical Technologies Inc. (BJCT) | Serono SA (Switzerland; NYSE:SRA) | Expanded licensing agreement for Vitajet3 system | Agreement expands Serono s rights to the Vitajet3 system to cover exclusive worldwide usage for all current and future growth hormone products and indications, including Saizen and Serostim; Serono also gains exclusive options to use all new technologies developed by Bioject in the delivery of growth hormone and has paid an undisclosed licensing fee to Bioject; further terms were ND (10/00) |
| Biolog Inc. | Paradigm Genetics Inc. (PDGM) | Licensing agreement for Biolog s Phenotype MicroArray technology | Paradigm will use the technology to determine gene function in agriculturally important fungal species; during the multiyear agreement, Paradigm will have nonexclusive rights to use products (9/00) |
| BioQuest Inc. (Pink Sheets: HIVX) | Biovector Therapeutics SA (France) | Evaluation and development/Therapeutic and potentially protective HIV vaccine combining BioQuest s cocktail of peptides from the HIV protein envelope and Biovec tor s technology for inducing immune responses using lipopeptide constructs to deliver cytotoxic T lymphocyte-inducing antigens through the major histocompatibility Class 1 pathway | Biovector will pay milestones and royalties (4/00) |
| BioSante Pharmaceuticals Inc. (OTC BB:BTPH) | ID Biomedical Corp. (Canada; TSE:IDB) | Option license/development of BioSante s calcium phosphate nanoparticle core technology as an adjuvant in a vaccine against group A streptococcus | BioSante will test its adjuvant and delivery system in a group A streptococcus vaccine and will formulate a second-generation vaccine using the technology and proprietary antigens from ID; ID also obtained a worldwide exclusive license to use the technology in future vaccines (6/00) |
| Biosite Diagnostics Inc. (BSTE) | Medarex Inc. (MEDX) | Research collaboration/creation of Trans-Phage Technology, a high-throughput method for creating fully human antibodies; the method combines Medarex s HuMAb-Mouse (for generating fully human monoclonal antibodies) with Biosite s Omniclonal phage display technology | Biosite and Medarex will offer pharmaceutical and biotechnology companies access to large volumes of high-affinity, fully human antibodies to validate genomic targets and to identify promising drug candidates; Biosite will receive research funding of $3M per year over eight years from Medarex, along with research fees, milestone payments and royalties; Biosite may also receive diagnostic rights to targets identified through the collaboration (6/00) |
| BioStar Inc. | Agouron Pharmaceuticals Inc. (unit of Pfizer Inc.; NYSE:PFE) | Amended agreement for BioStar s technology | Biostar granted Agouron a nonexclusive license, within a specified field of use, for BioStar s patented technology for optical detection of nucleic acids (9/00) |
| Biosyntech (Canada; OTC BB:BSYI) | Viragen Inc. (OTC BB:VRGN) and Viragen Europe (OTC BB:VERP) | Research collaboration/use of Biosyntech s BST-Gel as a sustained-release system for Viragen s Omniferon (natural, multi-subtype alpha interferon in Phase II trials for hepatitis C) | ND (3/00) |
| Biosyntech Canada Inc. (Canada; OTC BB:BSYI) | Biomet Inc. (BMET) | Research collaboration/use of Biosyntech s BST-GEL as a carrier for growth factor and gene delivery to accelerate fresh fracture repair of bones | ND (5/00) |
| Biota Holdings Ltd. (Australia; ASX:BTA) | Vapotronics Ltd. | Research collaboration/research effectiveness of aerosol applications | The companies will research the applications for one or more of Biota s drugs (10/00) |
| BioTools Inc. | DoubleTwist Inc. | Software partnership/DoubleTwist s Internet portal will provide BioTools PepTool and GeneTool products for protein and genomic sequence analysis | Full versions of both software tools will be available to all registered DoubleTwist.com users without charge (5/00) |
| Biovation Ltd. (Scotland) | Viragen Inc. (AMEX:VRA) and Procyon Biopharma Inc. (Canada; TSE:PBP) | Partnerships/use Biovation s DeImmunisation technology to develop therapeutic monoclonal antibodies | Biovation will receive research revenues, milestone payments and royalties (11/00) |
| Biovector Therapeutics | BioChem Pharma (Canada; BCHE) | Development/nasal vaccine against Streptococcus pneumoniae | The companies initiated the development process of a nasal vaccine against S. pneumoniae incorporating Biovector s proprietary drug delivery technology and BioChem s proprietary protein antigen; activities between the two companies will be coordinated at BioChem s vaccine development center in Northborough, Mass.; further details were ND (2/00) |
| BioVisioN H & Co. GmbKG (Germany) | Matrix Science Ltd. (UK) | Strategic alliance/long-term collaborations on developing bioinformatics focused technologies | The companies will combine their technologies in human peptide research and software for protein identification (12/00) |
| Boston Probes Inc. | PE Biosystems Group (NYSE:PEB) | Cross-license agreement/development and commer cialization of products employing peptide nucleic acid (PNA) technology for use in basic research, pharmaceutical discovery, diagnostic development, and food and environmental testing | PE Biosystems will hold a minority equity position in BPI and will be represented on the BPI board of directors; each company will have well-defined rights for its respective product offerings and for all sublicensing (6/00) |
| British Biotech plc (UK; LSE:BBG; BBIOY) | DevCo Pharmaceuticals Ltd. (UK) | Development/use of British Biotech s lexipafant, for the prophylaxis of certain serious neurological and renal complications associated with cardiac surgery | DevCo gains exclusive rights to develop, manufacture and sell lexipafant for the treatment of human disease other than in the fields of oncology and ophthalmology; DevCo will undertake all the development, and, if lexipafant is brought to market, pay British Biotech royalties (3/00) |
| British Biotech plc (UK; LSE:BBG; BBIOY) | Serono SA (Switzerland; NYSE:SRA) | Exclusive research, development and commercialization agreement | Serono and British Biotech will jointly research, develop and commercialize metalloenzyme inhibitors to treat serious inflammatory diseases; British Biotech will receive initial payment of US$5M, a series of undisclosed milestone payments and eventual royalties; companies will share research costs equally; Serono will cover product development costs, but British Biotech has the right to fund half of such costs and may co-promote products with Serono; cash payments and research funding to British Biotech could total between US$30M and US$80M (10/00) |
| British Biotech plc (UK; LSE:BBG; BBIOY) | BresaGen Ltd. (Australia; ASX:BGN) | Collaboration/develop and commercialize E21R for acute myeloid leukemia | British Biotech will make an equity investment of US$1M in BresaGen by issuing 1.1M new shares; it also will make up-front and milestone payments totaling US$7M; milestone payments could include include another US$6M if E21R is developed for other indications; also includes royalties (12/00) |
| BTG International Ltd.(unit of BTG plc; UK; LSE:BGC) | CeNeS Drug Delivery Ltd. (UK; unit of CeNeS Pharmaceuticals plc) | License/use of BTG s hydrogel technology for Moraxen, CeNeS 24-hour sustainedrelease morphine product recently submitted for marketing approval in the UK | Extension of licenses from BTG; new arrangement gives CeNeS worldwide rights to apply technology to any molecule other than prostaglandins and medicinal products for oromucosal use; BTG has waived rights to future milestone and royalty payments on the technology and will receive 2.02M (US$3.2M) for extending the term; BTG will pay 1.02M (US$1.6M) for 1.02M ordinary shares of CeNeS, and will buy an additional 1M (US$1.6M) worth of shares on 12/31/00; BTG will buy stock in two additional tranches of 1M (US$1.6M) apiece upon CeNeS reaching certain milestones, and CeNeS will make two further payments of 1M each to BTG upon reaching those same milestones (4/00) |
| Cadus Pharmaceutical Corp. (KDUS) | OSI Pharmaceuticals Inc. (OSIP) | License/G protein-coupled receptor technologies | OSI received a nonexclusive license to Cadus yeast G protein-coupled receptor technologies, including various reagents, a library of over 30,000 yeast strains and proprietary bioinformatics software; financial details were ND (2/00) |
| Caliper Technologies Corp. (CALP) | Millennium Pharmaceuticals Inc. (MLNM) | Technology access and application development/use of Caliper s LabChip microfluidic high-throughput technology platform | Collaboration provides for Millennium to subscribe to Caliper s Technology Access Program, as well as for joint investment in and development of novel LabChip applications focused on genomics and other areas of mutual interest (3/00) |
| Cambridge Antibody Technologies plc (UK; LSE:CAT) | Human Genome Sciences Inc. (HGSI) | Research collaboration/use of CAT s technology to develop an unlimited number of fully human antibodies for therapeutic and diagnostic purposes | Ten-year agreement providing HGS with rights to use CAT technology to develop and sell human antibodies, including research applications; CAT has right to select up to 24 HGS antigens for preclinical development, with HGS retaining option to share clinical development costs and share profits equally on up to 18 such products; HGS will buy 1.67M shares of CAT for $55M, a 20% premium; HGS also will pay $12M in licensing fees, including research support; HGS will pay milestones and royalties on products it develops (2/00) |
| Cambridge NeuroScience Inc. (OTC BB:CNSI) | Algos Pharmaceutical Corp. (ALGO) | License agreement/Algos patents related to pain products | Cambridge has been granted a paid-up license under three Algos patents to develop products for treatment of pain; Algos receives the right to negotiate to develop and/or commercialize these products (1/00) |
| CareScience Inc. (CARE) | British Biotech plc (UK; LSE:BBG; BBIOY) | Development/creation of a web-based analytical tool for acquiring, managing and evaluating clinical data in the field of oncology (an Oncology Extranet ) | British Biotech will have exclusive use of the Oncology Extranet for a limited period following development; thereafter, CareScience will market and sell the product with royalties to British Biotech; British Biotech will provide CareScience with development and service fees of US$1.5M over the first three years of the collaboration, and will have rights to purchase CareScience common stock under certain conditions; British Biotech will provide specialist assistance to define, test and validate the product (4/00) |
| Celera Genomics (NYSE:CRA) | Immunex Corp. (IMNX) | Database subscription/four of Celera s genomic products: the Human Genome Database, the Human Gene Index, the Drosophila Genome Database and the Mouse Genome Database | Immunex subscribed to four Celera products for five years; details were ND (6/00) |
| Celera Genomics (NYSE:CRA) | Life Technologies Inc. (OTC BB:LTEK) | Development collaboration/development of a large collection of clones containing human full-length genes and the corresponding DNA sequences of such genes | Gene sequence information will be used to annotate Celera s Human Genome Database, clones would be available from Life Technologies through an active link within the database; clones containing proprietary genes could be available to researchers in both academia and for-profit entities; the two companies will share revenues generated by the output resulting from this agreement, including sales of clones and licensing of intellectual property (7/00) |
| Celera Genomics (NYSE:CRA) | ValiGen NV | Five-year genomics agreement for a subscription to Celera s database products | ValiGen will receive a subscription to all of Celera s database products, bioinformatics systems and other discovery tools; financial terms were ND (9/00) |
| Celera Genomics (NYSE:CRA) | Lion Bioscience AG (Germany; Neuer Markt: LIO; LEON) | Strategic alliance to develop and deliver new software tools through the Celera Discovery System | The companies will collaborate to create improved software tools by further developing and customizing the Lion SRS system and developing new technologies (11/00) |
| Celera Genomics (NYSE:CRA) | Diversa Corp. (DVSA) | Collaboration/sequence genomes and discover genes selected, uncultured microorganisms | Companies will focus on genes contained in Diversa s environmental libraries; financial terms were ND (12/00) |
| Cell Genesys Inc. (CEGE) | Clontech Laboratories Inc. (unit of Becton Dickinson & Co.; NYSE:BDX) | License/retroviral gene delivery technology | Cell Genesys licensed certain retroviral gene delivery technology to Clontech; Cell Genesys will receive royalties on worldwide sales of research kits developed as a result of the collaboration, and on any future products employing its gene delivery technology; customers of Clontech who intend to market products arising from research using these kits will be required to obtain an additonal license to the technology from Cell Genesys prior to product comercialization; financial details were ND (1/00) |
| Cell Genesys Inc. (CEGE) | Xenogen Corp. | Evaluation license/access to Xenogen s in vivo imaging technologies | Cell Genesys will use the technology to develop cancer gene therapies (12/00) |
| CeNeS Pharmaceuticals plc (UK) | Bioglan Pharma plc (UK; LSE:BGP) | License and development agreement/use of Bioglan s aerosol technology to develop self-administered formulation of opiate analgesic | When CeNeS joins the Official List, Bioglan will buy 1M ordinary shares for 1M (US$1.6M), and has an option for an additional 2M (US$3.2M) worth in 2003; CeNeS gains exclusive rights to market the product in the European Union, and Bioglan has rights for the rest of the world; CeNeS will pay a license fee and royalties to Bioglan, which will run the development program; companies plan to enter an additional agreement under which Bioglan will supply the product to CeNeS (2/00) |
| Cetek Corp. | Cubist Pharmaceuticals Inc. (CBST) | Research collaboration/Cetek will develop capillary electrophoresis assays for a Cubist target and will screen the assays against Cubist s compound libraries | Formal agreement follows pilot study (1/00) |
| Chemdex Corp. (CMDX) | DoubleTwist Inc. | E-commerce agreement/three-year partnership to integrate the Chemdexe commerce solution into the DoubleTwist.com genomic research portal | Chemdex will make a strategic equity investment in DoubleTwist and will be the preferred provider of e-commerce services for DoubleTwist and its customers; the agreement simplifies procurement for DoubleTwist.com users who will automatically be notified when the supplies relevant to their online genomic research are available for purchase through the Chemdex marketplace (5/00) |
| Chiron Corp. (CHIR) | Biomira Inc. (Canada; BIOM) | Option exercise/Theratope therapeutic vaccine for metastatic breast cancer | Biomira will exercise its right to acquire Chiron s remaining rights to Theratope under a 1997 collaboration; Biomira will provide compensation to Chiron of $2.25M; upon U.S. regulatory approval and commercialization, Biomira will make one final payment to Chiron of $3.25M (6/00) |
| Chronix Biomedical | Hemispherx Biopharma Inc. (AMEX:HEB) | Research collaboration/Chronix s gene reshuffling technology; marketing of plasma RNA test that measures reshuffled genes (research use only) and use of Hemispherx s chronic fatigue syndrome database to identify gene sequences of relevance to CFS, Gulf War Syndrome and related chronic diseases | Companies jointly will develop intellectual properrty on new products for diagnosing the various stages of gene reshuffling; Hemispherix will assist in marketing Chronix s plasma RNA test and will take an equity stake in Chronix (3/00) |
| Chrysalis Biotechnology Inc. | OrthoLogic Corp. (OLGC) | Expansion of 1/99 license agreement/U.S. rights to orthopedic indications for Chrysalin, a synthetic 23-amino-acid peptide corresponding to a portion of thrombin | OrthoLogic will pay Chrysalis Biotechnology a one-time license fee of $2M to extend rights worldwide; OrthoLogic will pay certain milestone payments and royalty fees based upon the products developed and achievement of commercial success (7/00) |
| Clear Solutions Biotech | Laboratorios Sophia (Mexico) | Research collaboration/use of Clear Solutions hydrazide mediated crosslinking technology to link therapeutic genes to highmolecular weight hyaluronic acid, allowing for sustained delivery of genes to the eye for treatment of dry eye syndrome | Collaboration will be conducted with University of Guadalajara and with support of the federal government of Mexico (3/00) |
| Clingenix Inc. | MJ Life Co. (Taiwan) | Collaboration for new technologies | MJ Life will provide its laboratory services and expertise to Clingenix s pharmacogenomics capabilities and will provide samples and database information from clinical trials throughout Asia; MJ Life will have the first right of refusal to market in Asia all new methods and technologies that Clingenix develops in the collaboration; companies will share revenues; financial terms were ND (9/00) |
| Coelacanth Corp. | Microcide Pharmaceuticals Inc. (MCDE) | Research agreement/Coelacanth will provide novel libraries of compounds for screening in a broad range of Microcide assays directed at the identification of innovative antiviral, antifungal and antibacterial therapeutic agents | Microcide will have the worldwide rights to developcompounds that emerge from the agreement; Coelacanth will receive milestone payments during the drug development and approval process and royalties on product sales (6/00) |
| Cognetix Inc. | Elan Corp. plc (Ireland; NYSE:ELN) | License agreement and research collaboration/development and commercialization of Cognetix s contulakin-G (CGX-1160) for short-term management of post-operative pain using Elan s Medipad drug delivery system | Cognetix and Elan will license relevant technologies to a Cognetix subsidiary; Elan has made an equity investment in Cognetix and will support costs associated with the project (2/00) |
| Compugen Inc. (unit ofCompugen Ltd.; Israel; CGEN) | Motorola Inc. (NYSE:MOT) | Development and manufacturing agreement for DNA biochips | Motorola Life Sciences will develop and manufacture a number of DNA biochips using Compugen s chip design services (11/00) |
| Compugen Ltd. (Israel; CGEN) | Human Genome Sciences Inc. (HGSI) | Research collaboration/use of Compugen s LEADS computational analysis platform to analyze HGSI s collection of genes and create a chromosomal map of most expressed genes, a large collection of single nucleotide polymorphisms in expressed genes, and a comprehensive description of human gene organization and splicing variants | HGSI will pay Compugen a fixed multimilliondollar fee for work to be completed within 12 months, and will hold the exclusive rights to commercialize the results of the study (3/00) |
| Connetics Corp. (CNCT) | InterMune Pharmaceuticals Inc. (ITMN) | Acquisition of rights/rights to Actimmune (interferon-g-1b) revenue; Actimmune is FDA approved for chronic granulo matous disease and osteopetrosis | InterMune paid $5.2M for the remaining U.S. rights it did not own; prior to the transaction, Connetics had the right to recognize Actimmune revenue and related expenses associated with about the first $6.5M in U.S. sales in 2000 and 2001 (6/00) |
| Connetics Corp. (CNCT) | Alza Corp. (NYSE:AZA) | Agreement to develop an advanced drug delivery system | Companies will develop a system for Connetics recombinant human relaxin drug candidate, focusing on Alza s implantable drug delivery technology, or DUROS system; Connectics will pay all development costs and make milestone payments and royalties (10/00) |
| Corixa Corp. (CRXA) | QLT PhotoTherapeutics Inc. (Canada; QLTI) | Research collaboration/QLT will evaluate Corixa immunotherapeutic compounds in combination with photodynamic therapy | QLT will pay a fee for the exclusive right to use certain compounds for certain diseases, which QLT will evaluate in combination with photodynamic therapy; if successful, QLT s continued development of the Corixa technology would call for the generation of additional product candidates by Corixa in exchange for additional licencsing fees and royalties, and the potential purchase by QLT of some equity in Corixa at a premium (3/00) |
| Cortech Inc. (CRTQ) | United Therapeutics Corp. (UTHR) | License termination/UT-77, a serine elastase inhibitor based on preclinical results and Phase II testing | ND (6/00) |
| Coulter Pharmaceutical Inc. (CLTR) | Cobra Therapeutics Ltd. (unit of ML Laboratories; UK) | Joint development and commercialization of Cobra s platform gene expression technology | The companies will jointly develop and commercialize the Ubiquitous Chromatin Opening Elements technology; Coulter will make an up-front payment of 1M and milestone and sublicense fees; any products commercialized after the first two will be subject to a royalty fee; the agreement also allows for sublicensing of the technology; revenues from third-party milestone and royalty payments will be split equally (10/00) |
| Crucell NV (the Netherlands; CRXL) | Eurogene Ltd. (UK) | License/access to the PER.C6 technology | Eurogene will license the adenoviral packaging cell line for research purposes, with an option to convert to a commercial license within five years; Crucell will receive an up-front payment with further annual payments along with royalties on net sales (12/00) |
| Cubist Pharmaceuticals Inc. (CBST) | Emisphere Technologies Inc. (EMIS) | Research and development collaboration to use Emisphere s oral drug delivery technology for Cubist s product Cidecin and other lipopeptides | Emisphere could receive fees, research funding and milestone payments totaling $30M if a product is commercialized; Emisphere also would receive a potential royalty on sales; Cubist would be responsible for drug development and would receive exclusive worldwide commercialization rights to any oral products (11/00) |
| Cubist Pharmaceuticals Inc. (CBST) | International Health Management Associates Inc. | Acquisition of worldwide rights to oral ceftriaxone | Cubist acquired the rights to oral ceftriaxone, the first orally active version of the intravenous antibiotic, Rocephin; terms were ND (11/00) |
| CuraGen Corp. (CRGN) | COR Therapeutics Inc. (CORR) | Research collaboration/Application of CuraGen s functional genomics technologies to cardiovascular disease; the companies will use CuraGen s PathCalling proteomics technology and bioinformatics systems to create an annotated database of protein-protein interactions derived from cardiovascular endothelial cells | Expansion of 5/99 agreement to discover additional drug targets, as well as to offer functional information and validation of previously discovered targets (3/00) |
| CuraGen Corp. (CRGN) | Genentech Inc. (NYSE:DNA) | Research collaboration/Application of CuraGen s high-throughput functional genomic technologies and disease expertise to advance discovery of protein therapeutics and antibodies | Renewal of 1997 collaboration for a minimum of 2.5 years; Genentech will pay CuraGen research fees for access to technologies and databases; Genentech retains rights to license, develop and market therapeutics derived from these efforts; CuraGen also will receive milestone payments and royalties on sales (4/00) |
| CuraGen Corp. (CRGN) | Abgenix Inc. (ABGX) | Selection of 24 antibody drug targets in five-year strategic collaboration | The companies selected 24 antibody drug targets for further evaluation and possible development as cancer therapeutics; CuraGen and Abgenix are collaborating to identify and develop up to 120 antibody drug candidates against cancer, inflammation and autoimmune disease (8/00) |
| CuraGen Corp. (CRGN) | Biogen Inc. (BGEN) | Licensing agreement for five drug targets | CuraGen licensed five drug targets to Biogen, marking the completion of the research portion of their discovery collaboration; CuraGen is entitled to receive potential milestone payments and royalty payments, as well as additional milestone and royalty payments for other discoveries stemming from the research collaboration (10/00) |
| Cyclacel Ltd. (Scotland) | CV Therapeutics Inc. (CVTX) | Collaboration/determine the cancer-inhibition potential of CV s small-molecule compounds | Cyclacel will screen a library of compounds and also obtained the right to negotiate exclusive worldwide development and commercialization licenses for some compounds (12/00) |
| CytoTherapeutics Inc. (CTII) | Neurotech SA (France) | Technology sale/CytoTherapeutics Encapsulated Cell Technology | CytoTherapeutics will receive an initial payment of $3M, royalties on future product sales, and a portion of Neurotech revenues from third parties, in return for the assignment to Neurotech of intellectual property rights related to Encapsulated Cell Technology; in addition, CytoTherapeutics retains nonexclusive rights to use the technology in combination with stem-cell technology, and in the field of vaccines for infectious diseases (1/00) |
| CytoTherapeutics Inc. (CTII) | Genentech Inc. (NYSE:DNA) | Resolution of legal dispute/Dispute relates to 1996 collaborative agreement centering on CytoTherapeutics former encapsulated cell technology | Under certain circumstances, CytoTherapeutics was obligated to redeem a portion of the stock that Genentech had bought as part of the agreement; under the settlement agreement, CytoTherapeutics is relieved of the obligation (3/00) |
| Cytovax Biotechnologies Inc. (Canada) | BioChem Pharma Inc. (Canada; BCHE) | License and development/vaccine against Pseudomonas aeruginosa; collaboration includes a monoclonal antibody that could be used as a preventive or therapeutic agent | BioChem will commit research funding and expertise to the alliance and will purchase an equity stake in Cytovia, which also will receive development milestone payments and royalties; BioChem receives worldwide rights to develop, manufacture and market the products (6/00) |
| Cytovia Inc. | Axys Pharmaceuticals Inc. (AXPH) | Research collaboration/Use of Axys combinatorial chemistry library, medicinal chemistry, preclinical and clinical development strengths with Cytovia s high-throughput screening technologies, and molecular and cellular biology | Each company will fund its own research as part of the collaboration; Axys also is making an upfront equity investment in Cytovia; Axys will have the first right to develop any drug candidates that emerge and will pay Cytovia a royalty on any sales; Cytovia may exercise a profit-share option at a predetermined point during development in lieu of royalties; if exercised, Cytovia will share equally in profits and costs; if Axys chooses not to develop a drug candidate, Cytovia will have the right to do so, with Axys having the right to either profit sharing or royalties (3/00) |
| De Novo Pharmaceuticals Ltd. (UK) | British Biotech plc (UK; LSE:BBG; BBIOY) | Discovery agreement/British Biotech s existing inhouse research in antibacterial discovery will be enhanced | British Biotech has made an initial payment and will provide research funding for a period of 12 months; De Novo will apply its platform of computer algorithms to provide drug novel, small-molecule leads for British Biotech to exploit in its research; financial terms were ND (8/00) |
| D-Pharm Ltd. (Israel) | Nycomed Amersham plc (UK; NYSE:NYE; LSE:NAM) | Research collaboration to discover novel imaging agents | D-Pharm will apply its lipid vector technology to early stage compounds discovered by Nycomed (11/00) |
| DepoMed Inc. (AMEX:DMI) | Elan Corp. plc (Ireland; NYSE:ELN) | Joint venture/development of gastric retention oral drug delivery technologies and products using those technologies | Companies completed previously announced (12/99) agreement, creating DepoMed Development Ltd.; both JV partners will provide clinical development, regulatory and business guidance; Elan will make a $5M common-stock investment in DepoMed at $7 per share; DepoMed initially will own 80.1% of the JV while Elan retains the right to acquire up to 50% ownership; companies estimate program will require about $10M, with each contributing funding in proportion to its respective share ownership interests (1/00) |
| DepoMed Inc. (AMEX:DMI) | AVI BioPharma Inc. (AVII) | Development collaboration/feasibility of controlled oral delivery of AVI s proprietary Neugene antisense agents | Collaboration will involve developing oral formulations of one or more of AVI s products; scientists at AVI and DepoMed will work together to study feasibility of oral drug formulations based on DepoMed s Gastric Retention controlled-release system for delivery of the drug into the upper gastrointestinal tract (6/00) |
| Diaclone SA (unit of the Biotest Group; France) | Nexell Therapeutics Inc. (NEXL) | License agreements/access to seven Diaclone monoclonal antibodies for ex vivo cell therapy using Nexell s Isolex cell selection system | Companies signed two agreements, one of which grants Nexell an exclusive license to Diaclone s CD2 antibody for targeting T cells; the second agreement provides access to six additional antibodies, including CD138 (useful for purging myeloma cells), CD25 (a T-cell activation marker), CD56 and CD16 (markers for natural killer cells), CD14 (a monocyte marker), and CD4 (the marker for T-helper cells) (1/00) |
| Diaclone SA (unit of the Biotest Group; France) | Nexell Therapeutics Inc. (NEXL) | Conversion of 1/00 license agreement/Nexell gains exclusive rights to six monoclonal antibodies for use in ex vivo cell therapy (previous agreement conveyed nonexclusive rights) | The agreement also gives Nexell Therapeutics right of first refusal for potential in vivo applications of the antibodies and access to both finished product and master cell lines necessary to produce the six monoclonal antibodies; the portfolio includes CD138, useful for for purging myeloma cells; CD25, a T-cell activation marker that may facilitate the removal of alloreactive cells from a stem-cell graft prior to transplant; CD56 and CD16, markers for NK (natural killer) cells; CD14, a monocyte marker; and CD4, the marker for T-helper cells (6/00) |
| Digital Gene Technologies | Elan Corp. plc (Ireland; | Partnership-based research collaboration/use of Digital | Partnership will provide at least $58M in support; partners will share owne |
| Ecopia Biosciences (Canada) | Kosan BioSciences Inc. (KOSN) | Collaborative research and license agreement | Ecopia will apply its genomics platform in order to discover the genes responsible for directing the synthesis of a small molecule, which is of interest to Kosan, and that is naturally produced by an environmental microorganism; financial terms of the six-month agreement were ND (10/00) |
| Edenland Inc. | Hollis-Eden Pharmaceuticals Inc. (HEPH) | License agreement and research collaboration/technology that covers Hollis-Eden s lead HIV compound, HE2000 | Hollis-Eden reached a settlement on pending arbitration issues with Patrick Pendergast, chairman of Colthurst Ltd. and Edenland; parties replaced original Colthurst license agreement with a new agreement in which all patents, patent applications and potential improvements of the Colthurst technology will be irrevocably assigned to Hollis-Eden on a royalty-free basis in exchange for equity in Hollis-Eden; parties also entered a sponsored research agreement under which Edenland will license to Hollis-Eden a number of compounds and related patents and applications, and Hollis-Eden will fund additional preclinical research projects at Edenland, with licensing rights (and royalty obligations) for the results of the research (1/00) |
| Emisphere Technologies Inc. (EMIS) | Regeneron Pharmaceuticals Inc. (REGN) | Research collaboration/use of Emisphere s oral drug delivery technology for Regeneron s protein product candidate Axokine, which is in clinical trials for obesity | Emisphere could receive fees, research funding and milestones totaling $31M; Emisphere also will receive royalties; Regeneron has exclusive worldwide commercialization rights (3/00) |
| Enchira Biotechnology Corp. (ENBC) | Genencor International Inc. (GCOR) | License/use of Enchira s RACHITT system to develop gene-based products for the cleaning, textiles, grain processing, animal feed and good ingredients industries | Agreement includes up-front licensing fees, milestones and royalties (5/00) |
| EntreMed Inc. (ENMD) | Chiron Corp. (CHIR) | Manufacturing agreement for Endostatin | Chiron will continue production of bulk Endostatin protein for Phase II trials (10/00) |
| Epidauros Biotechnologie AG (Germany) | MWG Biotech AG (Germany; Neuer Markt:NWV) | Development collaboration/development of a pharmacogenomic chip to be used in clinical trials and at the bedside | MWG will pay DM10M (US$4.9M) up front, along with milestone and technology access fees; Epidauros is responsible for validation in more than 500 patients (4/00) |
| Eos Biotechnology Inc. | Medarex Inc. (MEDX) | Research collaboration/use of Medarex s HuMAb Mouse technology to create fully human antibodies to Eos targets associated with cancer and other diseases | Medarex will provide Eos up to $25M in cash, consisting of an initial payment of $5M and an additional $20M in milestones; Medarex also will provide Eos with credits against future milestones and royalties totaling $75M that would otherwise be payable in connection with Eos use of HuMAb Mouse technology over a multiyear period; Eos will develop six to nine products through Phase IIa, at which point they will be subject to joint ownership with Medarex; Medarex will have the option to obtain exclusive marketing rights in Europe for some of those products and may be retained by the alliance to perform GMP manufacturing services (2/00) |
| Eos Biotechnology Inc. | Biogen Inc. (BGEN) | Multiyear research and development collaboration to identify targets for antibody and protein therapeutics in the area of breast cancer | The value of the collaboration to Eos could reach $55M, not including royalties; the agreement also includes an option for Eos to produce fully human antibodies identfied in the collaboration; in return for providing Biogen with exclusive worldwide rights to breast cancer-specific molecules for use in the development of new therapeutics, Eos will receive an up-front payment, research funding and milestone and royalty payments on resulting products; Biogen also has made a $5M equity investment in Eos (9/00) |
| Epimmune Inc. (EPMN) | Valentis Inc. (VLTS) | Licensing agreement for Valentis PINC gene delivery technology | Epimmune will use PINC for its DNA vaccines against HIV and hepatitis C virus; nonexclusive license is in exchange for undisclosed up-front, milestone and royalty payments (12/00) |
| Epoch Biosciences (EBIO) | Applied Biosystems Group (NYSE:PEB) | Expanded relationship from a limited licensing agreement to a strategic alliance to incorporate Epoch s technology in the entire line of Applied s TagMan reagent products | Applied s TagMan probes will feature Epoch s minor groove binder technology; Applied will market the new probes and will fund research and pay supplemental license fees; other financial terms were ND (8/00) |
| EraGen Biosciences | TimeLogic Corp. | Marketing and development collaboration/to deliver tools for managing high-throughput sequence analysis by using EraGen s proprietary gene databases and TimeLogics high-speed computing | Both companies will promote each other s technologies through the creation of a channel partnership (7/00) |
| Etiogen Pharmaceuticals Inc. | Pathobiotek Diagnostics Inc. (PBTK) | Development collaboration/development of products for an activating virus discovered by Pathobiotek with potential applications in cancer diagnostics and therapeutics; Etiogen will work with Pathobiotek to complete the sequencing of the virus | Companies signed letter of intent for collaboration; products that will be licensed to third parties for marketing and distribution; diagnostic products are expected to be available by the end of 2000 (1/00) |
| Evotec BioSystems AG (Germany; Neuer Markt:EVT) | Sugen Inc. (unit of Pharmacia Corp.; NYSE:PHA) | Research collaboration/discovery and development of small-molecule drugs that target specific cellular transduction pathways; Evotec initially will screen Sugen phosphatase targets against Sugen compound libraries with aim of finding inhibitors | Evotec receives an up-front payment, a milestone payment upon completion of the first target screen and a final payment at the end of the collaboration; Sugen retains exclusive worldwide rights to commercialize products, while Evotec will be entitled to royalties on sales (3/00) |
| Exiqon A/S (Denmark) | Proligo LLC (joint venture between SKW Trostberg AG; Germany and Gilead Sciences Inc.; GILD) | Commercialization/sale of Exiqon s nucleic acid analog technology (oligonucleotides and monomers) | Proligo will have the right to manufacture and sell the oligonucleotides and monomers to third parties worldwide, while Exiqon will retain the right to develop and grant licenses for biochemical, diagnostic and therapeutic products containing LNA nucleic acid compositions (4/00) |
| FibroGen Inc. | ZymoGenetics Inc. | Research collaboration/development of new tissue sealant products for wound management | FibroGen will pair its recombinant human Type II collagen with ZymoGenetics recombinant human thrombin, a therapeutic protein critical for the clotting process; the companies plan to develop and potentially commercialize novel wound repair products (7/00) |
| Gemini Genomics plc (UK; GMNI) | CuraGen Corp. (CRGN) | Research collaboration/association of CuraGen s human genetic variants with disease traits derived from Gemini s database of clinical populations, in order to validate genes and genetic variants that are associated with complex diseases | Renewable two-year collaboration; CuraGen will apply the information discovered to drug development and pharmacogenomics (4/00) |
| Gemini Genomics plc (UK; GMNI) | CuraGen Corp. (CRGN) | Collaboration/Drug target discovery | Companies will apply CuraGen s PathCalling proteomic technology for ascertaining the biological context of disease-associated genes; the parties will jointly own intellectual property arising from the collaboration; they will commercialize the results by licensing the rights to discoveries (10/00) |
| Gemini Genomics plc (UK; GMNI) | Genmab A/S (Denmark; CSE:GEN) | Collaboration/develop products osteoporosis, cardiovas cular disease, for diabetes and obesity | Companies equally will share product rights and costs (12/00) |
| Gemini Holdings plc (UK) | Lineage Biomedical Inc. (Canada) | Joint venture/identification of genes for common diseases using the population resources of Newfoundland and Labrador, where certain diseases (including psoriasis, rheumatoid arthritis and diabetes) are more prevalent | Companies created Newfoundland Genomics and will establish a research facility in Newfoundland and Labrador to identify diseasecausing genes; any DNA collected in the province will remain in Newfoundland and Labrador; Gemini will provide a limited license to its genetic, computing, bioinformatic and scientific expertise, as well as funding some operating costs (2/00) |
| Genaissance Pharmaceuticals Inc. (GNSC) | Visible Genetics Inc. (VGIN) | Expansion of 1996 license agreement/includes research and diagnostic applications in all areas of sequence based DNA diagnostic testing | VGI has the right to sublicense the technology to third parties; the agreement covers the use of single-tube, single-step DNA sequencing technology, called CAS, covered by U.S. Patent No. 5,427,911 (6/00) |
| Gene Logic Inc. (GLGC) | Life Technologies Inc. (OTC BB:LTEK) | Development collaboration/fully sequence and patent the large number of human disease and predictive toxicology genes identified using Gene Logic s GeneExpress 2000 Suite of databases | Agreement provides for appropriate sharing between the two companies of revenues generated by outputs resulting from the collaboration, including sales of clones and databases, and licensing of intellectual property; as genes are identified they will be isolated by Life Technologies and sequenced and patented by Gene Logic (6/00) |
| Gene Logic Inc. (GLGC) | Psychiatric Genomics Inc. | Database subscription/Psychiatric subscribed to a por tion of Gene Logic s database system focusing on central nervous system samples | ND (6/00) |
| Gene Logic Inc. (GLGC) | Amersham Pharmacia Biotech K.K. (Japanese unit of Amersham Pharmacia Biotech Ltd.) | Alliance for distribution and marketing rights | Agreement grants Amersham exclusive distribution rights to market and sell GeneLogic s products to the Japanese market; Amersham will become the primary sales and marketing vehicle for Gene Logic s products in Japan; financial terms were ND (9/00) |
| Gene Logic Inc. (GLGC) | Biogen Inc. (BGEN) | Supply agreement/supply a gene expression database | Gene Logic will construct a customized database of gene expression data derived from its GeneExpress Suite (12/00) |
| Gene Tec Corp. | Applied Biosystems Group (NYSE:PEB) | Nonexclusive license agreement | Gene Tec granted Applied Biosystems a nonexclusive license to its patented method of amplifying nucleic acid targets directly in cells and viruses (8/00) |
| Gene-Cell Inc. (OTC BB:GCLL) | Athersys Inc. | Research collaboration/use of Gene-Cell s automated microinjection technology to deliver Athersys Synthetic Microchromosome vectors into human stem cells | ND (3/00) |
| GeneData AG (Switzerland) | Altana AG (Germany) | Multiyear alliance to establish new molecular approaches to drug research on the basis of computer-assisted analysis of functional genomics data | GeneData will provide access to its bioinformatics platform and will assist Altana s pharmaceutical group, Byk Gulden, in the analysis of functional genomics data (8/00) |
| GeneEd Inc. | Incyte Genomics Inc. (INCY) | Education/development of education programs linked to Incyte s genomics online database products | Incyte will make an equity investment in GeneEd (5/00) |
| Genencor International Inc. (GCOR) | Medarex Inc. (MEDX) | Expanded scope of licenses from Medarex | Genencor will develop, generate and use mice with transplanted human cells for research and development of commercial nonantibody therapeutic products (8/00) |
| Genencor International Inc. (GCOR) | Xgene Corp. | Expanded research collaboration | Companies will collaborate for an additional two years to develop tools to test compounds for activity against the human papilloma virus and test the efficacy of compounds in human skin inflammation; Xgene will complete development of an in vitro skin equivalent useful for testing in Genencor s compounds and will develop a second in vitro assay useful for testing the efficacy in dermatological disorders; Genencor will fund Xgene s research activities for the development of the tools and will receive exclusive rights to use the assays developed under the agreement (9/00) |
| Genencor International Inc. (GCOR) | Danisco A/S (Denmark) | Colloboration/discovery, development and production of bioingredients for use in the food industry | Genencor and Danisco entered into four-year agreement that provides up to $20M in funding for Genencor s research and development efforts (10/00) |
| Genencor International Inc. (GCOR) | Protein Polymer Technologies Inc. (OTC BB:PPTI) | Research collaboration/application of Protein Polymer s protein polymer designand production technology to design and develop new products with improved performance properties for industrial applications | Genencro receives a broad-based, worldwide exclusive license; Protein Polymer retains all rights to its technology for use in the development and commercialization of medical products and receives an up-front license fee, benchmark payments and royalties on sale of developed products (12/00) |
| Genentech Inc. (NYSE:DNA) | InterMune Pharmaceuticals Inc. (ITMN) | Acquisition of rights/broad range of indications of Actimmune in Canada, including chronic granulomatous disease, osteopetrosis, idiopathic pulmonary fibrosis and infectious diseases | InterMune will pay royalties on Canadian sales (8/00) |
| Genentech Inc. (NYSE:DNA) | Actelion Ltd. (Switzerland; SWX:ATLN) | Development and co-promotion agreement/for Actelion s endothelin receptor antagonist Tracleer (bosentan) in the U.S. | Both companies will be involved in the marketing and promotion of Tracleer, with Actelion taking the lead in the development efforts and commercialization; deal includes an up-front fee of $35M, as well as milestone payments that could make the deal worth $140M (12/00) |
| Geneva Proteomics Inc. (Switzerland) | Bruker Daltonics Inc. (BDAL) | Strategic alliance agreement in proteomics | Geneva Proteomics purchased 51 mass spectrometry systems, as well as consumables and support from Bruker; Bruker is making a strategic equity investment, in cash and stock, in Geneva Proteomics (9/00) |
| GenOdyssee SA (France) | UroGene SA (France) | Research collaboration/two year discovery of single nucleotide polymorphisms | UroGene will provide GenOdyssee with a list of relevant candidate genes for studying genetic predisposition to prostate cancer in the male population; UroGene will pay fees and milestones, as well as royalties (11/00**) |
| Genome Therapeutics Corp. (GENE) | ICAgen Inc. | Research collaboration/pharmacogenomics; use of Genome Therapeutics polymorphism detection platform to analyze genetic variations that could aid in design of clinical trials for an ICAgen ion channel target | Genome Therapeutics will seek to identify efficacy-related polymorphisms using its collection of DNA samples from various ethnic groups (2/00) |
| Genome Therapeutics Corp. (GENE) | Compugen Ltd. (Israel) | Commercialization/incorporation of Genome Therapeutics PathoGenome database of microbial genetic information into Compugen s LabOnWeb.com Internet portal | Compugen gains exclusive rights to make PathoGenome available over the Internet; companies will share revenues generated from customer use (4/00) |
| Genome Therapeutics Corp. (GENE) | Interleukin Genetics Inc. (ILGN) | Commercial research program/provide DNA sequencing information | Program will focus on key genes in the chromosomal region of 2q13, which may be associated with risk for inflammatory diseases; Genome will use its GTC Sequencing Center and the contract includes gene discovery and bacterial artificial chromosome screening across the interleukin-1 region; financial terms were ND (11/00) |
| Genometrix Inc. | Genomics Collaborative Inc. | Research collaboration to analzye DNA samples for profiling single nucleotide polymorphisms (SNPs) | The study will focus on hypertension and is designed to enable researchers to discover correlations between genetic variation and disease risk, toxicity assessments and drug response (8/00) |
| Genomic Solutions Inc. (GNSL) | Research Genetics (unit of Invitrogen Corp.; IVGN) | Nonexclusive agreement in which Research Genetics will supply PCR product to Genomic Solutions for printing on GeneMap microarrays | The libraries provided by Research Genetics consist of more than 40,000 human genes, 17,500 rat genes and 5,000 mouse genes; agreement also covers any libraries that Research Genetics offers in the future (10/00) |
| Genomic Solutions Inc. (GNSL) | Unnamed mass spectrometer companies | Collaboration for designing its Investigator Proteomic System | Genomic Solutions is collaborating with mass spectrometers from major manufacturers to design its Investigator Proteomic System (10/00) |
| Genomica Corp. | PE Biosystems Group (NYSE:PEB) | Development and reseller agreement/Genomica s genotyping analysis software, Genomica LinkMapper | PE Biosystems will co-market and exclusively distribute LinkMapper with its genotyping instruments and software (5/00) |
| Genomica Corp. | Genome Therapeutics Corp. (GENE) | Software licensing agreement | Genomica licensed its Discovery Manager software to Genome Therapeutics; financial terms were ND (9/00) |
| Genomics Collaborative Inc. | Qiagen Genomics Inc. (unit of Qiagen NV; the Netherlands; QGENF) | Development collaboration/development of an integrated solution combining GCI s sample repository and database services with Qiagen s single nucleotide polymorphism genotyping services | ND (7/00) |
| Genomics Collaborative Inc. | PolyGenyx | Research collaboration for discovering correlations between genetic variation and disease risk | Collaboration will apply PolyGenyx s highthroughput HaploScan technology to single-nucleotide polymorphism haplotyping; study will focus on coronary artery disease; financial terms were ND (9/00) |
| Genta Inc. (GNTA) | Oasis Biosciences Inc. | Nonexclusive license agreement for antisense patents | Agreement includes up-front payments in cash and royalties on product sales; Genta retains rights to the patents for its own use, as well as an exclusive right to grant unrestricted sublicenses to other users (9/00) |
| Genzyme General (GENZ) | Cambridge Antibody Technology plc (UK; LSE:CAT) | Strategic alliance to develop and commercialize human monoclonal antibodies directed against TGF-b | Companies will initially focus on developing a fully human monoclonal antibody-based treatment for scleroderma; Genzyme received an exclusive worldwide license to Cambridge s fully human antibodies directed against TGF-b for all uses excluding ophthalmology; Genzyme also has received a nonexclusive worldwide license for nonantibody antagonists of TGF-b in exchange for milestones and royalties; research, development and commercialization activities will be funded jointly and the partners will share profits; Genzyme will make a $20M equity investment in Cambridge (9/00) |
| Genzyme Molecular Oncology (GZMO) | Compugen Ltd. (Israel) | Database collaboration/integration of GMO s SAGE gene expression database into Compugen s www.labonweb.com site and use of the database with Compugen s LEADS platform | Companies signed two separate agreements under which they will share revenues related to the SAGE database; under the first agreement, companies will share revenue generated by customer use of SAGE on Compugen s web site; under second agreement, the SAGE database will be integrated into Compugen s LEADS platform, providing potential royalties to GMO on sales of the platform (1/00) |
| Genzyme Molecular Oncology (GZMO) | Affymetrix Inc. (AFFX) | License agreement/Genzyme Molecular exclusively licensed certain high-density DNA array diagnostic and research rights related to the p53 gene to Affymetrix for use in its GeneChip arrays | Genzyme Molecular Oncology will receive an upfront payment, milestones and minimum royalties on the sale of future GeneChip products that utilize the p53 gene; the license will allow GeneChip array customers to conduct microarray-based p53 tests without seeking an additional license from Genzyme (6/00) |
| Genzyme Molecular Oncology (GZMO) | Medical Molecular Research Cologne (Germany) | License agreement/Genzyme s SAGE (Serial Analysis of Gene Expression) technology | Medical Molecular Research will make the SAGE techology available to customers in Europe and will offer a complete range of SAGE services, including RNA preparation, library construction, sequencing of SAGE transcripts, bioinformatics analysis and target validation (6/00) |
| Genzyme Molecular Oncology (GZMO) | NeuralStem Biopharmaceuticals Ltd. | License/Genzyme s SAGE (Serial Analysis of Gene Expression) genomics tech nology for evaluation of global gene expression from NeuralStem s human central nervous system stem cells | Genzyme Molecular Oncology will receive an up-front payment and additional fees related to the creation of SAGE data by NeuralStem and transfer of NeuralStem SAGE data to third parties; NeuralStem has an option to extend the SAGE license for up to five years (7/00) |
| Genzyme Molecular Oncology (GZMO) | Myriad Genetics Inc. (MYGN) | Licensing agreement for Genzyme s cancer diagnostic patent rights related to an undisclosed gene implicated in hereditary colon cancer | Genzyme received an up-front payment and will receive royalties on each Colaris test performed; further financial details were ND (8/00) |
| Genzyme Molecular Oncology (GZMO) | Celera Genomics (NYSE:CRA) | Co-exclusive worldwide marketing agreement for the SAGE database | Genzyme granted Celera rights to market the SAGE (Serial Analysis of Gene Expression) database to Celera customers; Genzyme will license the database on a revenue-sharing basis; further details were ND (9/00) |
| Genzyme Molecular Oncology (GZMO) | Invitrogen Corp. (IVGN) | Exclusive worldwide license agreement for SAGE | Genzyme and Invitrogen signed a licensing agreement granting Invitrogen exclusive worldwide rights to sell SAGE (Serial Analysis of Gene Expression) genomics technology in standardized reagent kits; Genzyme will receive an up-front payment and royalties on sales of each kit (10/00) |
| Genzyme Transgenics Corp. (GZTC) | Progenics Pharmaceuticals Inc. (PGNX) | Research collaboration/development of a transgenic source of supply for Progenics PRO 542 anti-HIV drug | Expanded agreement based on successful feasibility studies; Genzyme Transgenics will develop transgenic goats that produce PRO 542 in their milk in exchange for fees and milestones; Genzyme Transgenics will supply clinical trial materials, and the agreement contemplates eventual commercial supply (2/00) |
| Genzyme Transgenics Corp. (GZTC) | Centocor Inc. (unit of Johnson & Johnson; NYSE:JNJ) | Production agreement/production of a Centocor monoclonal antibody using Genzyme Transgenics technology for antibody production in the milk of transgenic goats | Expansion of 12/98 agreement to include a second antibody; Genzyme Transgenics will provide the milk-expressed antibody to Centocor in exchange for undisclosed fees and milestone payments (3/00) |
| Genzyme Transgenics Inc. (GZTC) | Abgenix Inc. (ABGX) | Production agreement/Genzyme Transgenics will develop transgenic goats that express the therapeutic antibody ABX-IL8 in their milk | Genzyme Transgenics will receive fees and milestones (5/00) |
| Genzyme Transgenics Corp. (GZTC) | Sumitomo Metals Industries Ltd. (Japan) | Dissolved 10-year-old joint venture | Genzyme re-acquired its rights to technology for the production of medicines from milk in 18 Asian countries, including Japan; the rights were reacquired for 333,334 shares of Genzyme s stock, worth about $11.8M (10/00) |
| Genzyme Transgenics Corp. (GZTC) | Genzyme Corp. (GENZ) | Agreement/re-acquire rights in Europe and the Americas for recombinant human antithrombin III (rhATIII) | Terms and conditions were ND pending a final agreement, which was expected around the end of December (11/00) |
| Genzyme Transgenics Corp. (GZTC) | ImmunoGen Inc. (IMGN) | Agreement/GTC to produce humanized monoclonal antibody, huN901, in goat milk | ImmunoGen will use the antibody in its tumoractivated prodrug huN901-DMI/BB10901, being developed to treat small-cell lung cancer (11/00) |
| Geron Corp. (GERN) | Modex Therapeutics SA (France) | License/use of Geron s telomerase technology in Modex s encapsulated cell therapy system | Geron and Modex will share all income that Modex receives for products developed and commercialized under the license (5/00) |
| Geron Corp. (GERN) | Celera Genomics (NYSE:CRA) | Research collaboration/combines Geron s expertise in human pluripotent stem cell biology with Celera s comprehensive sequencing information and gene discovery capabilities | Celera and Geron will work together to uncover important discoveries pertaining to the use and/or function of genes involved in human cell differentiation; Geron will develop and commercialize a number of small-molecule drug, protein therapeutic, celland gene-therapy products and prenatal diagnostics; Celera will use the information to enhance the annotation of the human genome and develop and commercialize probe sets for gene expression analysis; Celera and Geron will license to third parties certain intellectual property to develop other products (6/00) |
| Gilead Sciences Inc. (GILD) | EyeTech Pharmaceuticals Inc. | License/therapeutic uses of Gilead s aptamer NX1938, an inhibitor of vascular endothelial growth factor (known to play a role in ophthalmic diseases) | EyeTech paid an up-front licensing fee of $7M, and Gilead is entitled to additional cash payments of up to $25M based upon achievement of development milestones; EyeTech will be responsible for all R&D costs and will pay royalties on sales; EyeTech also issued Gilead a warrant to purchase 0.83M shares (at $6 each) of convertible preferred stock (4/00) |
| GyneLogix Inc. | The Medicines Company (MDCO) | License agreement/GyneLogix s CTV-05, a strain of human Lactobacillus with applications in urogenital and reproductive health; initial indication is for treatment of bacterial vaginosis | Medicines gains exclusive worldwide rights (1/00) |
| HeavenlyDoor.com Inc. (HVDC) | Interneuron Pharmaceuticals Inc. (IPIC) | Development and commercialization contract/HeavenlyDoor.com s PRO 2000, a candidate topical microbicide that has been shown to prevent infection by HIV and other sexually transmitted pathogens | Interneuron gains exclusive worldwide rights to PRO 2000 in exchange for an up-front license fee, clinical trial milestone payments and royalties on net sales; Interneuron is responsible for all remaining preclinical development, clinical testing, regulatory review and commercialization activities in connection with PRO 2000 (6/00) |
| hte GmbH (Germany) | Molecular Simulations . Inc. (unit of Pharmacopeia Inc.; PCOP) | Development collaboration/use of MSI s informatics expertise to develop software for hte s high-throughput experi mentation products; hte gains access to MSI s combinatorial chemistry and materials simulation software in support of its external and internal research projects | MSI will distribute the software modules developed in the collaboration (5/00) |
| HTS Biosystems Inc. | Boston Probes Inc. and Applied Biosystems Group (NYSE:PEB) | Licensing agreement for PNA technology | HTS received a combined license from Boston Probes and Applied Biosystems for the use of peptide nucleic acid technology in the field of proteomics; HTS will pay Boston Probes an upfront fee, maintenance fees and royalties from product sales (10/00) |
| Human Genome Sciences Inc. (HGSI) | Vical Inc. (VICL) | Reciprocal license agreement/use of HGS genes and Vical s naked DNA gene delivery technology | Companies entered reciprocal royalty-bearing license under which Vical has the option to exclusively license up to three genes from the HGS database for gene-based product development; HGS has the option to license Vical s naked DNA gene delivery technology for use in up to three gene-based products; in a related deal Vascular Genetics Inc. licensed Vical s delivery technology (2/00) |
| Human Genome Sciences Inc. (HGSI) | Cambridge Antibody Technology plc (UK; LSE:CAT) | Extended collaboration agreement/development of B-Lymphocyte Stimu lator (BLyS) | Companies studied BLyS, which may serve as a treatment for autoimmune and neoplastic disorders, as part of their August 1999 pact; CAT will be entitled to receive license fees, clinical development milestones and royalties on product sales; financial details were ND (10/00) |
| Hyseq Inc. (HYSQ) | Chiron Corp. (CHIR) | Extension of research collaboration/discovery of genes for use in development of solid-tumor cancer therapeutics, diagnostic molecules and vaccines | Two-year extension (5/00) |
| Ibis Therapeutics (unit of Isis Pharmaceuticals Inc.; ISIP) | Agouron Pharmaceuticals Inc. (unit of Pfizer Inc.; NYSE:PFE) | Development agreement/dis covery and development of small-molecule drugs against certain RNA targets | The collaboration will focus on discovering drugs that bind to RNA using Ibis expertise in smallmolecule drug discovery; Agouron will fund collaborative research, pay an up-front technology access fee and make milestone payments totaling $37M for the first product; Agouron will develop and commercialize drugs discovered by the collaboration and will pay Isis royalties on sales (6/00) |
| ICAgen Inc. | NPS Allelix (Canada; unit of NPS Pharmaceuticals Inc.; NPSP) | License agreement/nervous system-specific sodium channel gene technology | ICAgen obtained a sole license for the technology and obtained exclusive rights to storeor receptoroperated calcium channels from the University of California, Los Angeles (8/00) |
| ICOS Corp. (ICOS) | Array BioPharma (ARRY) | Expanded drug discovery collaboration/process research and manufacturing agreement | ICOS has exclusive worldwide rights to develop and market any products resulting from the collaboration; ICOS will provide funding and make milestone payments for the development and commercialization of resulting products (8/00) |
| ID Biomedical Corp. (Canada; IDBE) | PE Biosystems Group (NYSE:PEB) | License agreement/ID Biomedical s intellectual property for Cycling Probe Technology | The license grants PE Biosystems access to ID Biomedical s intellectual property concerning its Cycling Probe Technology; PE will pay ID Biomedical royalties based on future product sales, as well as an up-front license fee of $5M (6/00) |
| ID Biomedical Corp. (Canada; IDBE) | DiscoveRx Corp. | License option/DiscoveRx will explore the combination of ID s Cycling Probe Technology with its own enzyme fragmentation technology | ID received an equity stake in DiscoveRx; in exchange for an 18-month option to obtain a worldwide, nonexclusive license; the royalty-bearing license, if obtained, will will require an additional payment of $5M (7/00) |
| Idun Pharmaceuticals | Elan Corp. plc (Ireland; NYSE:ELN) | Research collaboration/development of compounds for treating stroke | Companies completed negotiations to form a wholly owned subsidiary of Idun that will focus on the stroke program; within subsisidiary, companies will collaborate on continuing the development of a series of drug candidates licensed from both parties that have demonstrated activity in animal models (2/00) |
| ImClone Systems Inc. (IMCL) | Lonza Biologics (unit of Lonza Group Ltd.; Switzerland) | Manufacturing agreement/ImClone s lead cancer therapeutic, IMC-C225 | The agreement calls for Lonza to be a secondsource manufacturer of IMC-C225 (9/00) |
| Immunex Corp. (IMNX) | Cambridge Antibody Technology plc (UK; LSE:CAT) | Partnership/phage display library access and eight exclusive therapeutic antibody product options | Agreement includes a license fee, milestone and royalty payments to CAT in exchange for CAT s antibody library for reagent generation and target validation, and eight options to develop MAbs (12/00) |
| Immunicon Corp. | Therakos Inc. | Research collaboration/exploration of applications of Immunicon s magnetic separation technology with Therakos cell therapy technology in the field of extracorporeal photoimmune therapy | ND (3/00) |
| ImmunoDesigned Molecules (France) | Medarex Inc. (MEDX) | Licensing and distribution agreement for therapeutic rights | IDM will attain the right to use certain therapeutic products developed by Medarex, including MDX210, MDX-220 and MDX-447; IDM obtained worldwide rights to MDX-210 and more limited rights to the other two products; Medarex increased its equity stake in IDM from 6% to 34% (11/00**) |
| ImmunoGen Inc. (IMGN) | British Biotech plc (UK; LSE:BBG; BBIOY) | Development and marketing agreement/ImmunoGen s huN901-DMI tumor-activated prodrug for treatment of small-cell lung cancer | British Biotech gains an exclusive right to develop and commercialize huN901-DM1 in the European Union and Japan and will pay an up-front fee of $1.5M for those rights (5/00) |
| ImmunoGen Inc. (IMGN) | Genentech Inc. (NYSE:DNA) | Research collaboration/use of ImmunoGen s maytansinoid tumor-activated prodrug technology with Genentech antibodies | Five-year agreement under which Genentech will provide an up-front technology access fee of $3M and potential milestones of nearly $40M per antigen target, plus royalties on sales of resulting products; Genentech is responsible for manufacturing, product development and marketing; ImmunoGen will be reimbursed for any preclinical materials that it makes under the agreement; the agreement can be renewed for one three-year period for an additional technology access fee; agreement is the second between the two companies; the first centered on development of a TAP conjugate version of Genentech s Herceptin (5/00) |
| Immunomedics Inc. (IMMU) | Amgen Inc. (AMGN) | License/for a novel cancer therapeutic antibody, epratuzumab, to treat indolent and aggressive non-Hodgkin s lymphoma | Amgen gains the rights to develop and commercialize epratuzumab in North America and Australia; Amgen also will be responsible for commercial manufacturing and will receive rights to second-generation CD22 products; the agreement includes an $18M up-front payment, clinical milestone payments potentially totaling $65M, and royalties; it also provides for one-time sales milestone payments totaling $50M to $225M if and when annual net sales reach $500M to $1B (12/00) |
| Incyte Genomics Inc. (INCY) | Biogen Inc. (BGEN) | Database access/Incyte s LifeSeq Gold gene database and LifeTools data management software | Incyte could receive milestones and royalties on sales of products developed with its technology and database information (1/00) |
| Incyte Genomics Inc. (INCY) | Corixa Corp. (CRXA) | Database access/Incyte s Incyte s LifeSeq Gold gene database for use in Corixa s efforts to develop vaccines, monoclonal antibodies and diagnostics | Incyte could receive milestones and royalties on products developed using the Incyte technology and information (2/00) |
| Incyte Genomics Inc. (INCY) | Vertex Pharmaceuticals Inc. (VRTX) | Database access/Incyte s LifeSeq Gold gene database for use in small-molecule drug discovery | Incyte could receive future milestones and royalties on products developed using the Incyte technology and information (2/00) |
| Incyte Genomics Inc. (INCY) | Elitra Pharmaceuticals Inc. (ELIT) | Antimicrobial genomics collaboration | Incyte will provide Elitra an exclusive license to Incyte s PathoSeq microbial sequence database technologies and Elitra will obtain the right to market and sell the database to third parties; Incyte will receive equity in Elitra (7/00) |
| Incyte Genomics Inc. (INCY) | Sankyo Co. Ltd. (Japan) | Licensing agreement/Incyte s LifeSeq Gold database | Sankyo gained the rights to LifeSeq, as well as the ZooSeq animal model database, via the web site (11/00) |
| Incyte Genomics Inc. (INCY) | NEN Life Science Products (unit of PerkinElmer Inc.; NYSE:PKI) | Licensing agreement/cDNA clone collection from Incyte s LifeSeq Gold database | NEN will gain access to Incyte s collection of cDNA clones from LifeSeq Gold for the commercialization of microarrays; Incyte will receive royalties on sales; financial terms were ND (10/00) |
| Incyte Genomics Inc. (INCY) | Sequenom Inc. (SQNM) | Collaboration to create SNP assays for use in genetics research | Companies will work together to create single nucleotide polymorphism assays; Incyte will license SNPs to Sequenom, which will provide Incyte with access to the mass-array technology and validation strategies; financial terms were ND (10/00) |
| Incyte Genomics Inc. (INCY) | Galapagos Genomics NV (the Netherlands) | Collaboration/conduct functional genomics studies on fulllength genes | Galapagos will generate a recombinant adenoviral library containing full-length genes selected from Incyte s LifeSeq Gold collection for use in discoveringand validating gene function; financial terms were ND (11/00) |
| InforMax Inc. (INMX) | Structural Bioinformatics Inc. | Distribution agreement for SBI s database content of atomic resolution 3-D protein models | The database will be offered to GenoMax customers (9/00) |
| InKine Pharmaceutical Co. (INKP) | Innovex (unit of Quintiles Transnational Corp.; QTRN) | Contract sales and marketing/Innovex will launch and promote Diacol (under FDA review) for cleansing of the bowel prior to diagnostic procedures such as colonoscopy | InKine retains rights and control of the product (5/00) |
| Intellivax International Inc. | Active Biotech AB (Sweden; ACTIB) | Development collaboration/aimed at developing a vaccine for prevention of infections with Group A, b-hemolytic streptococci (GAS) | The initial collaboration will strive to prove the feasibility of the vaccine; Intellivax will couple its proteosome delivery platform with Active Biotech s GAS antigen to create a novel nasal spray vaccine (6/00) |
| Interferon Sciences Inc. (OTC BB:IFSC) | Metacine Inc. | Option to purchase about 50% of Metacine s common stock | An independent third party will conduct a review and analysis of Metacine s intellectual property, under terms of the agreement; the option was acquired for $100,000 and may be exercised during the 60day period following ISI s receipt of the review; if exercised, Metacine will issue 43% of its common stock to ISI, which also will receive a warrant to purchase additional shares for up to 5 years (10/00) |
| Intergen Co. | Amersham Pharmacia Biotech Inc. (UK; owned by Nycomed; NYSE:NYE; and Pharmacia Corp.; NYSE:PHA) | License/AP Biotech will use Intergen s Amplifluor to en able detection in its Rolling Circle Amplification technology for ultra-sensitive, highthroughput detection of single nucleotide polymorphisms | Licensing agreement (3/00) |
| InterMune Pharmaceuticals Inc. (ITMN) | Genentech Inc. (NYSE:DNA) | License agreement/InterMune received exclusive rights to commercialize Actimmune in Japan for treatment and prevention of chronic granulomatous disease or osteopetrosis | Genentech will receive royalty payments on all sales in Japan; prior to obtaining these additional commercialization rights, Intermune had exclusive rights to commercialize this product in Japan for infectious tuberculosis (8/00) |
| Invitrogen Corp. (IVGN) | Affymetrix Inc. (AFFX) | Development agreement/development and market ing of new software for microarray analysis | Invitrogen has agreed to adapt its Pathways microarray analysis software for use in analyzing images of spotted arrays generated with the Affymetrix s 417 Arrayer and scanned with the 418 Array Scanner (6/00) |
| Isis Pharmaceuticals Inc. (ISIP) | Elan Corp. plc (Ireland; NYSE:ELN) | Development collaboration/ISIS 14803, a clinical-stage antisense drug that inhibits hepatitis C virus replication | Companies signed a binding letter of agreement to create a new subsidiary of Isis for development of the drug; Elan will purchase $7.5M of Isis common stock in 1Q:00 and possibly an additional $7.5M as a milestone; both tranches are at a premium to market price; Elan also will purchase convertible preferred stock in Isis and will make available a $12M line of credit for Isis funding commitment to the subsidiary (1/00) |
| Karo Bio USA (unit of Karo Bio AB; Sweden; SSE:KARO) | GPC Biotech AG (Germany; Neuer Markt:GPC) | Development collaboration/development of a new generation of broad-spectrum antibiotics, based on up to 15 of GPC s genomics-derived antibacterial targets; Karo Bio USA is developing highthroughput screening assays | GPC is funding development of assays and will pay Karo Bio USA royalties on compound development or outlicensing by GPC Biotech; commercialization rights are retained by GPC Biotech; Karo Bio has the potential to obtain access to targets that GPC Biotech does not advance (6/00) |
| KS Biomedix Holdings plc (UK; LSE:KSB) | Eukarion Inc. | Research and development collaboration/Eukarion s antibody lipidation and chemical modification technologies | The technologies could enable KSB s sheep monoclonal antibodies to be exploited against novel disease targets (8/00) |
| LactoFerrin Products Co. | Manatech Inc. | Marketing agreement for exclusive worldwide distribution rights for immune-supporting agents | Agreement is for a combination of immunesupporting agents, including Prime Colustrum, a mucosal-delivery growth and repair factor containing product harvested from newborn hormonefree dairy cattle; financial terms were ND (10/00) |
| Large Scale Biology Corp. (LSBC) | Dow AgroSciences LLC (unit of Dow Chemical Co.; NYSE:DOW) | Completion of a strategic collaboration milestone | Large Scale announced that it completed the fifth milestone in the strategic collaboration by delivering to Dow a fully, functional, metabolic pathway database; total funding to date exceeds US$45M over the first two years of the three-year agreement (9/00) |
| Large Scale Proteomics Corp. (unit of Large Scale Biology Corp.; LSBC) | Biosite Diagnostics Inc. (BSTE) | Research collaboration/use of LargeScale s proteomic discovery technologies to identify targets from Biosite s patient samples | Biosite will retain target rights for develop ment and commercialization of in vitro diagnostics resulting from the alliance; Large Scale will retain target rights for other potential therapeutic and diagnostic uses; companies will share revenues from resulting products (5/00) |
| Lexicon Genetics Inc. (LEXG) | Millennium Pharmaceuticals Inc. (MLNM) | Expansion of 7/99 research collaboration/use of Lexicon s knockout mouse technology to create knockouts based on Millennium targets | Agreement triples the size of the initial numbers of mouse models Lexicon will generate, and commits Millennium to obtain certain numbers of knockout mice from Lexicon during each year of the collaboration (6/00) |
| Lexicon Genetics Inc. (LEXG) | Arena Pharmaceuticals Inc. (ARNA) | Joint research collaboration using Lexicon s functional genomics technology Seek Target Validation program and Arena s CART technology to produce knockoutvalidated chemical leads for small-molecule drug candi dates, which target G protein-coupled receptors (GPCRs) | Each company will share equally, providing equal numbers of GPCRs to be validated simulataneously and in up-front fees, milestones and royalties generated from products developed from alliance; they will fund their own efforts; they may agree to jointly fund development of compounds targeting alliance GPCRs, although each intends to partner the majority of the drug targets (8/00) |
| Lexicon Genetics Inc. (LEXG) | Affymetrix Inc. (AFFX) | Supply agreement for GeneChip technology | Lexicon will obtain GeneChip technology for its internal drug discovery program, initially applying it to its oncology program (9/00) |
| Lexicon Genetics Inc. (LEXG) | Biogen Inc. (BGEN) | Nonexclusive sublicense for Lexicon s positive-negative selection technology for the generation of knockout mice | Biogen will use the technology in its internal drug discovery and target validation programs; financial terms were ND (9/00) |
| Lexicon Genetics Inc. (LEXG) | Tularik Inc. (TLRK) | Multiyear functional genomics research agreement | Tularik will have access to conditional knockouts and gene-specific knockouts, generated using Lexicon s gene targeting program, with genetic alterations directed at specific drug targets selected by Tularik; Tularik also will have access to the OmniBank library of knockout mouse clones; financial terms were ND (10/00) |
| Life Technologies Inc. (OTC BB: LTEK) | Amgen Inc. (AMGN) | Research collaboration/use of Life s full-length cDNA library technology to complement Amgen s gene discovery efforts | Terms call for a payment for each full length cDNA library constructed, as well as payments for each full-length clone selected by Amgen for discovery research (2/00) |
| LION Bioscience AG (Germany; LEON) | Nestle Research Center (Switzerland) | License agreement for the data integration technology SRS and other technologies | LION licensed the technology, including its gene and genome annotation system bioScout, the microarray analysis system arrayScout, as well as genomeScout, Lion s genome comparison software (11/00) |
| Lorus Therapeutics Inc. (Canada; OTC BB: LORFF) | AVI BioPharma Inc. (AVII) | Research collaboration/evaluation and co-development of antisense drug therapies for cancer and infectious diseases; AVI will contribute its Neugene-based antisense backbone; Lorus will contribute cancer and infectious disease targets and will spearhead the collaborative research program by performing molecular, cell and animal biology experiments | Each company will retain an ownership interest in any jointly developed compound, and drugs discovered together may also be developed independently with royalty payments to the other party (7/00) |
| Lorus Therapeutics Inc. (Canada; TSE:LOR; LORFF) | Proligo (joint venture between SKW Trostberg AG and Gilead Sciences Inc.; GILD) | Strategic supply alliance | Lorus entered into an alliance with Proligo, which will invest in resources to increase the capacity of the production process for GTI-2040 to supply the product for Phase II trials (10/00) |
| Luminex Corp. (LMNX) | Orchid BioSciences Inc. (ORCH) | Development collaboration/development of an affordable, rapid-throughput system for conducting single nucleotide polymorphism (SNP) scoring | The new SNPstream will use Orchid s proprietary line of SNPware reagent kits and is based on Luminex s open-platform LabMAP system; Orchid will market the product line (5/00) |
| Luminex Corp. (LMNX) | Life Technologies Inc. (OTC BB: LTEK.OB) | Multiyear strategic partnership/reagents and instrumentation based on Luminex s LabMAP technology | Life was granted worldwide nonexclusive rights to develop and distribute reagents and instrumentation; Luminex received an up-front payment and will receive future royalties on potential products (8/00) |
| Luminex Corp. (LMNX) | Upstate Biotechnology | Strategic partnership/develop reagents and assay kits | Companies will develop the reagents and assay kits for basic research and drug discovery applications based on Luminex s LabMAP technology (10/00) |
| Luminex Corp. (LMNX) | One Lambda Inc. | Development agreement/human leukocyte antigen based typing applications tissue | Multiyear strategic partnership with One Lambda, which receives worldwide nonexclusive rights to develop and distribute reagents and instrumentation based on the LabMAP technology in return for making an up-front payment to Luminex and paying royalties (11/00) |
| Luminex Corp. (LMNX) | Bio-Rad Laboratories Inc. (AMEX: BIO.A, BIO.B) | Strategic partnership/commerciaize a system for drug discovery applications based on the LabMAP technology | BioRad has incorporated Luminex s microsphere-based assay technology and reader in an integrated system to allow researchers to easily extract more data from small samples (12/00) |
| Luminex Corp. (LMNX) | BioSource International (BIOI) | Strategic partnership/develop reagents and assay kits for basic research and drug discovery | The new assay detection system will be based on Luminex s LabMAP technology (12/00) |
| Luminex Corp. (LMNX) | MiraiBio Inc. (formerly Hitachi Genetic Systems) | Multiyear distribution agreement/reagents and instrumentation based on Luminex s LabMap technology | MiraiBio has worldwide nonexclusive rights (12/00) |
| Lynx Therapeutics Inc. (LYNX) | Hybrigenics SA (France) | Research collaboration/discovery of expressed genes and protein interactions and pathways in human obesity | Companies said they will jointly exploit opportunities arising from the data (5/00) |
| Lynx Therapeutics Inc. (LYNX) | Genomics Collaborative Inc. | Strategic corporate partnership/identification of a comprehensive set of diabetes associated SNPs | Scientists from both companies designed a study to conduct a genome-wide scan for single nucleotide polymorphisms (SNPs) associated with Type II diabetes; financial terms were ND (8/00) |
| Lynx Therapeutics Inc. (LYNX) | Molecular Engines Laboratories SA (France) | Two-year research collaboration to identify differentially expressed genes associated with tumor reversion | Lynx will apply its Megasort technology to cancer cell lines provided by MEL; Lynx also will receive payments for genomic discovery services, and royalty payments; other financial terms were ND (10/00) |
| Magainin Pharmaceuticals Inc. (MAGN) | Genentech Inc. (NYSE:DNA) | Development collaboration/Magainin s antibody to interleukin-9 (a potential asthma treatment), with options for other products | Genentech will make a $5.5M up-front equity purchase, plus provide up to $60M in milestones and development funding for the first product; additional products could generate further milestones and development support (4/00) |
| Magainin Pharmaceuticals Inc. (MAGN) | Genentech Inc. (NYSE:DNA) | Termination of license and collaboration dated April 28, 2000, covering the IL-9 antibody development program and related respiratory technology | The original deal was worth $65.5M to Magainin; Genentech had made an up-front payment of $5.5M in an equity investment (12/00) |
| Maxim Pharmaceuticals Inc. (MAXM) | BioChem Pharma Inc. (Canada; BCHE) | License/molecules capable of inducing cancer cells to die by activating the caspase enzyme system and triggering apoptosis | Companies will collaborate on lead optimization, after which BioChem will take over the clinical development of any drugs; BioChem will provide Maxim licensing fees, research support and milestones of up to $55M (7/00) |
| Maxygen Inc. (MAXY) | Chevron Research and Technology Co. | Three-year agreement/develop novel bioprocesses for specific petrochemical products | Chevron will have commercialization rights in exchange for license fees, technology access fees, full research funding, milestones, annual fees and product royalties (10/00) |
| Maxygen Inc. (MAXY) | Integrated Genomics Inc. | Collaboration allowing Maxygen access to Integrated Genomics bioinformatics software and databases | Financial terms were ND (12/00) |
| MDS Proteomics Inc. | Zyomyx Inc. | Collaboration/companies conduct research to prove protein biochips use in mass spectrometry-based proteomic studies | MDS purchased an equity stake in Zyomyx for $2.5M as part of Zyomyx Series D financing; MDS also will provide funding to support research and development (12/00) |
| Medarex Inc. (MEDX) | Raven Biotechnologies Inc. | Research collaboration/use of Medarex s HuMAb Mouse technology to develop fully human antibodies against multiple Raven antigens | Medarex could receive research payments, license fees and milestone payments, as well as royalties on sales (3/00) |
| Medarex Inc. (MEDX) | Regeneron Pharmaceuticals Inc. (REGN) | Research collaboration/use of Medarex s HuMAb Mouse technology to create fully human antibodies to targets identified by Regeneron, including growth factors, cytokines and receptors | The companies have selected more than 20 initial targets and plan to add more in the future; they will share preclinical and clinical responsibilities and will jointly market any resulting products (3/00) |
| Medarex Inc. (MEDX) | Coulter Pharmaceutical Inc. (CLTR) | Research collaboration and license option/use of Medarex s HuMAb Mouse technology to generate fully human monoclonal antibodies against a number of specific target antigens | Coulter will have the option to obtain exclusive commercial rights to the antibodies; in return, Medarex could receive R&D payments, license fees and milestone payments, as well as royalties on sales (4/00) |
| Medarex Inc. (MEDX) | Genmab A/S (Denmark; Medarex joint venture with BankInvest) | Research collaboration/use of Medarex s HuMAb Mouse technology to develop fully human antibodies | Expanded agreement gives Genmab the ability to create an unlimited number of antibody products using HuMAb Mouse (4/00) |
| Medarex Inc. (MEDX) | Centocor Inc. (unit of Johnson & Johnson; NYSE:JNJ) | Research collaboration/access to Medarex s HuMAb-Mouse technology for making fully human monoclonal antibodies | Medarex will receive technology access fees, and could also receive license fees, milestones and royalties on product sales (5/00) |
| Medarex Inc. (MEDX) | Corixa Corp. (CRXA) | Development collaboration/use of Medarex s HuMAb Mouse to generate fully human monoclonal technology anti bodies against selected targets from Corixa s library of autoimmune disease, cancer and infectious disease antigens | Corixa and Medarex will hold a closed auction between the two parties for rights to develop the specific antibody-based product when antibodies are jointly determined to be worthy of clinical investigation; the company with the winning bid will pay the bid amount in cash to the other company and will be responsible for all product development and commercialization expenses and decisions; the other company will receive future product development milestone payments and royalties on future product sales (6/00) |
| Medarex Inc. (MEDX) | MedImmune Inc. (MEDI) | Development agreement/use of Medarex s HuMAb-Mouse technology to generate fully human monoclonal antibodies to MedImmune antigens | MedImmune receives an exclusive, worldwide license for the use of Medarex s HuMAb-Mouse technology for the development of antibodies against respiratory syncytial virus (RSV) and an option to further license the use of this technology for additional antigens; Medarex receives technology access fees and could also receive license and milestone payments, as well as royalties on product sales (6/00) |
| Medarex Inc. (MEDX) | Athersys Inc. | Collaboration to develop therapeutics produced through joint application of the HuMAbthe mouse technology and Athersys RAGE technology | Companies plan to jointly discover, develop and commercialize fully human antibodies as therapeutics for cancer and other diseases; Athersys acquired an option to obtain access to Medarex s technology for targets outside the collaboration; Medarex acquired an option to obtain access to validated therapeutic targets produced with RAGEment in Athersys (8/00) |
| Medarex Inc. (MEDX) | Oxford GlycoSciences plc (UK; LSE:OGS; OGSI) | Alliance/develop therapeutics produced using Medarex s human monoclonal antibody fully technology and OGS s proteomics technology | Companies will jointly discover, develop and commercialize fully human antibodies as therapeutics; they expect OGS to provide up to 30 protein targets for cancer or other life-threatening diseases; companies will share preclinical and clinical responsibilities, and intend to jointly commercialize resulting products; Medarex will make a $5M equity investment in OGS (9/00) |
| Medarex Inc. (MEDX) | ImmunoDesigned Molecules SA (France) | Definitive agreement/IDM acquired rights to certain Medarex products and technology | IDM acquired worldwide rights to use Medarex s MDX-210 anti-HER2 product in conection with cell therapy, as well as MDX-220 and MDX-447 in all fields; Medarex increased its ownership interest in IDM from 6% to about 34%; the definitive agreement supercedes the agreement announced in February; IDM will not acquire rights to MDX-33, MDX-22 and certain Medarex research programs (10/00) |
| Medarex Inc. (MEDX) | ZymoGenetics Inc. | Alliance/develop fully human antibody products | Companies will combine Medarex s fully human monoclonal antibody development technology and ZymoGenetics expertise in the field of genomics and protein therapeutics to create antibodies to multiple disease products; ZymoGenetics is responsible for the development and commercialization of resulting products; Medarex expects to receive license fees and milestone payments, as well as royalties on potential sales (10/00) |
| Medarex Inc. (MEDX) | Epigen Inc. | Research, development and marketing collaboration | The companies will share equally in preclinical and clinical development for antibody-based cancer therapeutics, as well as commercialization (11/00) |
| MedImmune Inc. (MEDI) | MGI Pharma Inc. (MOGN) | Asset purchase agreement for Hexalen (altretamine) | MGI Pharma will pay $7.2M, plus royalties on sales for 10 years of the chemotherapeutic agent, which is approved in the U.S. for ovarian cancer, to MedImmune over an 18-month period; MGI Pharma will assume full product responsibilities early in 2001 (11/00) |
| Meditech Pharmaceuticals Inc. (OTC BB:MDCH) | Immune Network Research Ltd. (CDNX:IMM) | License/Meditech s MTCH-24, an over-the-counter herpes simplex medication, and Viraplex, a cancer therapy | Immune Network exercised an option to a worldwide exclusive license (excluding the U.S.) and paid a licensing fee of $0.1M (5/00) |
| Mermaid Pharmaceuticals GmbH (Germany) | Gene Tools LLC | Alliance/examine the biological function of the majority of vertebrate genes | Collaboration will combine the Morpholino antisense technology with high-throughput in organismo screening technology in zebrafish (11/00) |
| MethylGene Inc. (Canada) | MGI Pharma Inc. (MOGN) | Development agreement/MethylGene s MG98 mRNA inhibitor and small-molecule DNA methyltransferase inhibitors for cancer | MGI will make an initial cash payment to MethylGene, and will pay milestones and royalties on sales; MethylGene retains a co-promotion right in North America and all rights outside North America; the initial and milestone payments could total approximately $16M for each of the two development programs; MGI will invest an additional $6.8M in MethylGene equity (8/00) |
| Microbiotix Inc. | BioChem Pharma Inc. (Canada; BCHE) | Research collaboration/identification and development of inhibitors of enzymes that are essential for bacterial DNA replication; goal is to create new antibi otics for resistant organisms | Three-year collaboration under which BioChem will contribute research funding and personnel and also will take an equity stake in Microbiotix; BioChem also may pay milestones and royalties on resulting products (2/00) |
| MicroMed Technology Inc. | Chrysalis Vascular Technologies (unit of Chrysalis BioTechnology Inc.) | Evaluation agreement/evaluation of the effectiveness of Chrysalin, a synthetic version of a portion of thrombin, in promoting regeneration of blood vessels in the heart | Upon conclusion of this evaluation, MicroMed will have the exclusive optionto license Chrysalin worldwide for myocardial revascularization (7/00) |
| Millennium Predictive Medicine Inc. (unit of Millennium Pharmaceuticals Inc.; MLNM) | Becton Dickinson and Co. (NYSE:BDX) | License/use of Millennium markers to develop colon cancer diagnostics | Becton Dickinson paid a licensing fee for certain markers and related intellectual property and has an option for a commercial license (7/00) |
| Molecular Applications Group | Structural Bioinformatics Inc. | Bioinformatics purchase/MAG s GeneMine technology for enhancement of SBI s protein structural databases | Purchase agreement (1/00) |
| Molecular Biosystems Inc. (MBIO) | Genta Inc. (GNTA) | License/broad portfolio of MBI patents and technology that relate to antisense for therapeutic and diagnostic applications | The agreement includes grants of both exclusive and nonexclusive rights to Genta from MBI on a royalty-free basis in return for cash MBI on a Genta common stock (6/00) |
| Molecular Simulations Inc. (unit of Pharmacopeia Inc.; PCOP) | Abbott Laboratories (NYSE:ABT), Cytoclonal Pharmaceuticals Inc. (CYPH), Emerald Biostructures Inc., Exelixis Inc. (EXEL) and Genencor International Inc. (GCOR) | Establishment of a new highthroughput crystallography consortium | Research project is intended to accelerate drug research by developing and validating rapid methods for X-ray structure determination in structural biology (12/00) |
| Morphochem AG (Germany) | Synt:em Inc. (France) | Strategic alliance/discover and develop novel therapeutics | Morphochem and Synt:em entered into a strategic alliance to discover, validate and develop products up to clinical trials with the initial focus to be on new antiviral compounds (10/00) |
| MorphoSys AG (Germany; Neuer Markt: MORG) | Millennium Pharmaceuticals Inc. (MLNM) | Research collaboration/MorphoSys will apply its HuCAL technology to generate human antibodies for a new target molecule in inflammatory disorders provided by Millennium; deal covers up to six additional targets | Expansion of 8/98 collaboration between MorphoSys and LeukoSite (since acquired by Millennium); under the agreement, MorphoSys receives an up-front payment and R&D funding, as well as milestone payments and royalties on sales (3/00) |
| MorphoSys AG (Germany; Neuer Markt: MORG) | Eos Biotechnology Inc. | Research collaboration/MorphoSys HuCAL (Human Combinatorial Antibody Library) technology for antibody generation | Eos will pay technology license fees to MorphoSys as well as make milestone and royalty payments on any antibody therapeutics; Eos has an option to develop certain antibodies as therapeutics (6/00) |
| MorphoSys AG (Germany; Neuer Markt: MORG) | ImmunoGen Inc. (IMGN) | Collaboration to develop human antibodies | Two companies will collaborate on the development of human antibodies to treat cancer; MorphoSys will receive a technology access payment, as well as development-related milestone payments and royalties on marketed products; financial details were ND (10/00) |
| Motorola Inc. (BioChip Systems unit; NYSE:MOT) | Iconix Pharmaceuticals Inc. | Strategic relationship to enable the creation of a next-generation chemical genomic database | Iconix will validate the beta release of Motorola s new CodeLink Expression System in the multiyear agreement; Motorola has made an equity investment in Iconix and received rights to distribute the resulting Iconix ChemExpress database as part of future BioChip System solutions (8/00) |
| Motorola Inc. (NYSE:MOT) | Incyte Genomics Inc. (INCY) | Licensing agreement for the rights to Incyte s gene sequence databases and gene patent portfolio, including LifeSeq Gold human gene sequence database and ZooSeq animal gene sequence database | Motorola has licensed Incyte s patented gene sequences to develop, manufacture and sell gene expression chips, or bioarrays; Motorola expects to commercialize DNA bioarrays; expects to receive royalties; financial terms were ND (8/00) |
| Myriad Genetics Inc. | Encore Pha | License/rights to develop, | Myriad acquired the exclusive worldwide rights |
| Nabi (NABI) | Collaborative BioAlliance Inc. (affiliate of The Collaborative Group Ltd.) | Production and supply agreement/Nabi StaphVax (Staphylococcus aureus type 5 and type 8 Capsular Polysaccharide Conjugate Vaccine) at CBA s cGMP bio-manufacturing facility in Smithfield, R.I. | ND (5/00) |
| Nanogen Inc. (NGEN) | Hitachi Ltd., Nissei Sangyo Co. Ltd. and Hitachi Instruments Service Co. Ltd. (Japan) | Collaboration/development, manufacturing and distribution of products based on Nanogen s and Hitachi s technologies | The 10-year agreement provides the framework for a joint investment of about $57M in applications development funding; further investments could exceed $140M; Hitachi will make an equity investment in Nanogen; Nanogen will assist customers using the NanoChip Molecular Biology Workstation in developing diagnostic markers and in extending the NanoChip system s application menu to include gene expression, integrated amplification and protein analysis; Hitachi will provide annual funding for general applications development (8/00) |
| Nanoscale Combinatorial Synthesis Inc. | Euroscreen SA (Belgium) | Research collaboration/use of Nanoscale s smallmolecule libraries with Euroscreen s collection of cloned G protein-coupled receptors | Terms include access to Nanoscale s capabilities in follow-up synthesis and lead optimization (1/00) |
| NeoRx Inc. (NERX) | Nexell Therapeutics Inc. (NEXL) | License/in vitro diagnostic applications of NRLU-5 (also referred to as the Pan-05 antibody), a cell surface marker common to many tumor types | Nexell obtains a 10-year exclusive license for all in vitro diagnostic applications of the antibody (8/00) |
| NeuralStem BioPharmaceuticals Ltd. | Gene Logic Inc. (GLGC) | Equipment purchase, research collaboration/NeuralStem will use Gene Logic s GeneExpress database for drug discovery in central nervous system diseases; Gene Logic gains access to NeuralStem s repository of highly characterized stem cells for gene expression analysis and will include the resulting data in GeneExpress | NeuralStem purchased a GeneExpress module to become the fourth commercial customer of the database; additional terms were ND (4/00) |
| NeuralStem BioPharmaceuticals Ltd. | Gene Logic Inc. (GLGC) | License and database access/GeneLogic licensed Neural Stem s human central nervous system stem cell technology for gene expression, and NeuralStem puchased a module of Gene Logic s GeneExpress database | Gene Logic made an equity investment in NeuralStem, which will also make its CNS stem cell lines available to Gene Logic customers for discovery efforts and follow-on screening (5/00) |
| Neuronyx Inc. | Neose Technologies Inc. (NTEC) | Research and development collaboration/discovery and development of drugs for the treatment of Parkinson s disease and other neurological diseases | Neose made an investment in convertible preferred stock of Neuronyx; Neuronyx will focus on preclinical and clinical development of the compounds, and Neose will focus on the the synthesis and manufacturing scale-up of targeted compounds using its proprietary technologies for carbohydrate synthesis; Neose and Neuronyx will share in any financial benefit of the collaboration (6/00) |
| Nexell Therapeutics Inc. (NEXL) | NeoRx Corp. (NERX) | Exclusive license for 10 years for all in vitro diagnostic applications of the NRLU-5 antibody | Nexell obtained the rights to NRLU-5; financial terms were ND (8/00) |
| Northwest Biotherapeutics Inc. | Cytogen Corp. (CYTO) | Exclusive worldwide agreement for the sublicense of prostate specific membrane antigen | Agreement clarifies Northwest s right to make, have made, use and sublicense prostate specific membrane antigen, for ex vivo prostate cancer immunotherapy; terms were ND (8/00) |
| Northwest Biotherapeutics Inc. | Protein Sciences Corp. | Kidney cancer target manufacturing contract | Northwest selected Protein Sciences to develop a high-yield expression vector for production of a kidney cancer-specific protein as a component of a new treatment for renal cell carcinoma; terms were ND (10/00) |
| NPS Allelix Corp. (Canada; unit of NPS Pharmaceuticals Inc.; NPSP) | Forest Laboratories Inc. (NYSE:FRX) | Agreement for the development and worldwide marketing of ALX-0646 to treat migraine headache | Further details were ND (8/00) |
| NPS Allelix Corp. (Canada; unit of NPS Pharmaceuticals Inc.; NPSP) | ICAgen Inc. | License/NPS Allelix s nervoussystem specific sodium channel gene technology | ND (8/00) |
| NsGene A/S (Denmark) | Biogen Inc. (BGEN) | Research and development agreement/research and poten tial development and commercialization of products based on Neublastin, a novel neurotrophic protein | Biogen has the rights to pursue research, development and commercialization of therapies based on Neublastin for indications outside the central nervous system; if a product based on Neublastin is successfully developed and commercialized by Biogen, NsGene may receive royalties, as well as fees and milestone payments totaling over $20M; NsGene retains the rights to develop Neublastin for the treatment of diseases of the nervous system, with the exception of multiple sclerosis (6/00) |
| NsGene A/S (Denmark) | Neurotech SA (France) | Collaboration and license agreements regarding the and development of Neurotech s research Encapsulated Cell Technology to treat neurological and eye disorders | NsGene will focus its development efforts on ECT products to treat neurodegenerative disorders and epilepsy, while Neurotech will focus on the treatment of diseases of the eye and cancer; NsGene paid Neurotech an undisclosed up-front fee and both parties will receive cross royalties on potential products (8/00) |
| Oncotech Inc. | Beckman Coulter Inc. (NYSE:BEC) | Strategic alliance to develop and commercialize gene expression technologies that can be used to diagnose cancer | The companies will collaborate on discovery of new genetic markers for early stage malignancies in colon, ovarian, breast, prostate and lung cancers (8/00) |
| Ontogeny Inc. (now Curis Inc.; CRIS) | Biogen Inc. (BGEN) | Return of rights under 7/96 agreement/Ontogeny s hedgehog protein technology for inducing formation or regeneration of tissues | Biogen has elected to return to Ontogeny the rights from the 7/96 agreement to develop and commercialize hedgehog protein products, follow ing a portfolio review (7/00) |
| Orchid BioSciences Inc. (ORCH) | Amersham Pharmacia Biotech (owned by Nycomed Amersham plc; UK; NYSE: NYE; and Pharmacia Corp.; NYSE:PHA) | License/Orchid s SNP-IT singlebase primer extension technology for single nucleotide polymorphism applications | Amersham will produce and sell reagent kits and software incorporating Orchid s technology under the brand name SNuPe (6/00) |
| Orchid BioSciences Inc. (ORCH) | PE Biosystems Group (NYSE:PEB) | License/use of Orchid s SNP-IT single-base primer extension technology for single nucleotide polymorphism analysis | PE will use the technology in its ABI Prism reagent kits, including SNaPshot ddNTP Primer Extension kits (6/00) |
| Orchid BioSciences Inc. (ORCH) | Millennium Pharmaceuticals Inc. (MLNM) | Service agreement/Orchid will score single nucleotide polymorphisms on samples provided by Millennium | ND (7/00) |
| Orchid BioSciences Inc. (ORCH) | Tecan (Switzerland; SWX:TECN) | Strategic partnership for the supply of systems solutions for DNA processing | Tecan will supply Orchid with its automated DNA processing solution for use in the manufacture of SNPware consumable kits; financial terms were ND (9/00) |
| Orchid BioSciences Inc. (ORCH) | DNAPrint Genomics Inc. (Pink Sheets: DNAP) | Purchasing agreement for Orchid s SNPstream 25K system | DNAPrint agreed to purchase Orchid s SNPstream 25K system for single nucleotide polymorphism scoring; DNAPrint will make an upfront payment and will purchase SNPware consumables on a per-unit basis; other details were ND (10/00) |
| Orquest Inc. | Biopharm GmbH (Germany) | Research and development collaboration/development of products that combine Biopharm s MP52 recombinant bone morphogenic protein (a growth factor) and Orquest s materials and know-how for developing and assembling combinations of growth factors and matrices | Companies will pool their technologies to develop a portfolio of products that promote the growth of new tissues lost to degenerative disease or injury; the first product, HealosMP52, is expected to enter clinical studies shortly in the U.S. and Europe for spinal fusion in collaboration with Sulzer Spine-Tech (4/00) |
| Oxford BioMedica plc (UK; LSE:OXB) | Immuno-Designed Molecules SA (France) | Research collaboration/development of anticancer cell therapy products incorporating Oxford s immunecell genetic engineering technology and IDM s technology for manipulating individual patients immune cells | Oxford and IDM jointly will develop and share revenues from therapeutics (1/00) |
| Oxford BioMedica plc (UK; LSE:OXB) | InforMax Inc. (INMX) | Software licensing agreement | Companies agreed to enter discussions about marketing jointly the genetic information produced from BioMedica s gene discovery programs; BioMedica will retain full commercial licensing rights to the genes themselves and the products derived from them (9/00) |
| Oxford GlycoSciences plc (UK; LSE:OGS; OGSI) | Packard BioScience Co. (PBSC) | Collaboration to develop protein biochips | Companies will apply their respective technolologies to develop protein biochips (9/00) |
| Oxford GlycoSciences plc (UK; LSE:OGS; OGSI) | Incyte Genomics Inc. (INCY) | Revised alliance/create content for Incyte s LifeExpress product offering | Companies will move from an exclusive profitsharing arrangement to a nonexclusive contract payment basis; Incyte will retain its rights to market LifeExpress; financial terms were ND (11/00) |
| Oxford Molecular Group plc (UK; LSE:OMG) | Pharmocopeia Inc. (PCOP) | Definitive agreement to acquire OMG s software subsidiary | Pharmacopeia will acquire OMG s software business for $27M, comprised of cash and the assumption of certain liabilities (8/00) |
| Packard BioScience Co. (PBSC) | Agencourt Bioscience Corp. | Strategic marketing alliance | The two companies have agreed to co-market their respective products for nucleic acid purification; Packard purchased an equity stake of less than 10% in Agencourt (10/00) |
| Packard BioScience Co. (PBSC) | Xenometrix Inc. (OTC BB:XENO) | License agreement/gene expression profiling | Worldwide nonexclusive license covers the collection of gene expression profiles using all platforms, including biochips and high-density microarrays (11/00) |
| Paracel Inc. | Tularik Inc. (TLRK) | Equipment installation/Paracel s GeneMatcher genetic data analysis system | Paracel installed the system at Tularik (2/00) |
| Paracelsian Inc. (OTC BB:PRLN) | Triangle Laboratories Inc. | Strategic partnership/joins Paracelsian s dioxin screening Ah Immunoassay with Triangle s high-resolution gas chromatography/high-resolution mass spectrometry testing | The agreement also provides for a later development and worldwide co-marketing deal for the combined system (12/00) |
| Paradigm Genetics Inc. (PDGM) | Lion Bioscience AG (Germany; LEON) | Strategic alliance/co-develop and co-market a new plant and fungal metabolic profiling database for five years | The database will be used for target identification and validation; the alliance is an expansion to the one initiated in January 2000; companies will share revenues from sale of the database, bioinformatics tools and solutions that result from the alliance (11/00) |
| Paradigm Genetics Inc. (PDGM) | Prionics AG (Switzerland) | Extended collaboration/codevelop and co-market bloodbased diagnostics for the rapid detection of Creutzfeld Jakob disease in humans and bovine encephalopathy in cattle | The parties will continue to share development costs and Paradigm will receive a royalty on any product developed as a result (12/00) |
| Paradigm Genetics Inc. (PDGM) | Rosetta Inpharmatics (RSTA) and Agilent Technologies Inc. (NYSE:A) | License/Rosetta Resolver Expression Data Analysis System | Financial terms were ND (12/00) |
| PathoGenesis Corp. (PGNS) | Chiron Corp. (CHIR) | Research collaboration/development of new antibiotics through use of PathoGenesis expertise in bacterial target discovery and antibiotic development, along with Chiron s combinatorial chemistry library and screening expertise | Work is funded in part by PathoGenesis $14M grant from the Cystic Fibrosis Foundation (1/00) |
| PE Biosystems Group (NYSE:PEB) | Visible Genetics Inc. (VGIN) | License/use of PE technology to manufacture and sell DNA sequencing instruments, as well as clinical sequencing kits to run on the instruments; development of diagnostics based on the technology | Agreement resolves a patent dispute PE filed against Visible; Visible will pay a $25M licensing fee over four years, as well as royalties on sales (4/00) |
| PE Biosystems Group (NYSE:PEB) | Cepheid (CPHD) | License/manufacture and sale of thermal cyclers for use in the polymerase chain reaction process | License agreement grants rights under both PCR process patents and PE s amplification system patent regarding thermal cyclers and applies to Cepheid s family of I-CORE systems (5/00) |
| PE Biosystems Group (NYSE:PEB) | Geneva Proteomics Inc. | Access agreement/Applied s Maldi TOF/TOF mass spectrometer and ICAT reagents | Geneva will deploy the mass spectrometers and reagents with the initial delivery of early access versions of the technologies in the first half of 2001 (11/00) |
| Pharmacopeia Inc. (PCOP) | Progenics Pharmaceuticals Inc. (PGNX) | Research collaboration/discovery of small-molecule HIV therapeutics, focusing on compounds that block attachment of the virus to CD4 | Progenics will provide technologies and expertise related to the interaction between HIV and CD4, and Pharmacopeia will provide its lead discovery services, including high-throughput screening of its internal compound library; Progenics will obtain exclusive licenses to all active compounds identified; Pharmacopeia will receive fees for screening services, as well as milestones and royalties on resulting products (3/00) |
| Pharmacopeia Inc. (PCOP) | PE Biosystems Group (NYSE:PEB) and BD Biosciences (unit of Becton, Dickinson and Co. (NYSE:BDX) | License/incorporation of Pharmacopeia s high-throughput screening technology based on confocal microscopy | PE and BD Biosciences obtained a co-exclusive license, and will co-develop instrumentation which can deploy the technology in connection with their high-throughput screening systems for sale to third parties; Pharmacopeia received an upfront payment from PE and BD Biosciences and will receive royalties on sales by the companies and their sublicensees; in addition, PE Biosystems and BD Biosciences will develop and deliver to Pharmacopeia a custom instrument for ultra-highthroughput screening for use internally at Pharmacopeia (4/00) |
| Pharsight Corp. (PHST) | Guilford Pharmaceuticals Inc. (GLFD) | Technology collaboration/companies will deploy Phar sight s software, methodologies and consulting services to accelerate Guilford s clinical development programs | Three-year agreement (5/00) |
| Phytera Inc. | Novelos Therapeutics Inc. | Development and commercialization agreement for BAM-002 | Phytera obtained exclusive North American rights to the cancer agent BAM-002, which is in Phase I/II trials; the two companies will collaborate on the development of the agent and related products; Phytera will be responsible for marketing and Novelos for manufacturing; financial terms were ND (8/00) |
| PolyMASC Pharmaceuticals plc (unit of Valentis Inc.; VLTS) | Flemington Pharmaceutical Corp. (OTC BB:FLEM) | Research agreement/companies will work to develop a formulation of PEGylated insulin delivered by Flemington s Immediate-Immediate Release lingual spray system | Each party will be responsible for its own development costs; if the feasibility studies are successful, the companies intend to seek a corporate partner to assist in the development and marketing of the product (8/00) |
| PowderJect Pharmaceuticals plc (UK; LSE:PJP) | Aviron (AVIR) | Revised agreement for the manufacture of Aviron s FluMist | PowderJect said its subsidiary, Evans Vaccines Ltd., renegotiated the agreement; Aviron will make initial payments to PowderJect totaling $15M, with further payments of $4M per year for five years; PowderJect also will receive additional performance-based milestone payments of up to $3M (10/00) |
| PPD Discovery (unit of PPD Inc.; PPDI) | Agouron Pharmaceuticals Inc. (unit of Pfizer Inc.; NYSE:PFE) | Research collaboration/use of PPD Discovery s functional genomics system to identify human genes required for the replication of HIV | Agouron will provide an up-front payment and a technology access fee, as well as support research at PPD Discovery s genomics facility; PPD will receive R&D milestones and royalties on sales of resulting products; PPD retains rights to pharmacogenomic and diagnostic applications and products, and also may develop therapeutics that Agouron will have an option to license; Agouron will receive royalties on PPD Discovery diagnostic and pharmacogenomic products resulting from the collaboration (2/00) |
| PPD Discovery (unit of PPD Inc.; PPDI) | Agouron Pharmaceuticals Inc. (unit of Pfizer Inc.; NYSE:PFE) | Research agreement/alliance to identify new targets for selectively eradicating cancer cells; PPD Discovery s propri etary functional genomics platform, the GSX System, will be used to perform highthroughput genome-wide screening for Genetic Suppressor Elements (GSEs) capable of inducing programmed death of tumor cells | Agouron will provide an up-front payment and support research at PPD Discovery s genomics facility in Menlo Park, Calif; PPD will receive research and development milestone payments and royalties on sales of Agouron s products; PPD will retain certain rights to pharmacogenomic and diagnostic applications and products, with Agouron receiving royalties on sales of any diagnostic and pharmacogenomic products resulting from the collaboration (6/00) |
| PPGx Inc. (joint venture of PPD Inc.; PPDI; and Axys Pharmaceuticals Inc.; AXPH) | Spotfire Inc. | Bioinformatics/integration of PPGx s advanced pharmacogenomics data warehouse and information mining product, GeneTrials, with Spotfire s decision analytics portal, Spotfire.net | ND (5/00) |
| PPL Therapeutics (UK; LSE:PTH) | Undisclosed biotechnology company | Agreement/feasibility study for the transgenic production of a peptide that inhibits excess tissue formation | The companies will study the transgenic production of the peptide initially in the milk of rabbits; other details were ND (9/00) |
| PPL Therapeutics Inc. (Scotland; LSE:PTH) | Celentis Ltd. (New Zealand) | Joint venture/focused on production of pharmaceutical and nutraceutical proteins in the milk of transgenic cattle | The initial aim will be the production of a potential multiple sclerosis protein (12/00) |
| Praecis Pharmaceuticals Inc. | Human Genome Sciences Inc. (HGSI) | Research collaboration/use of Praecis screening technology for two HGS targets to identify small-molecule drugs for metabolic disorders and infectious diseases | ND (2/00) |
| Procyon Biopharma Inc. (Canada; TSE:PBP) | IMI International Medical Innovations Inc. (CDN:IMIN) | Development and commercialization/colorectal cancer screening tests | Companies signed a letter of intent to consolidate their colorectal cancer tests, with IMI to lead development, clinical trials and commercialization efforts; Procyon will provide scientific support, contribute funding and share pro rata in the initiative s revenues; joint initiative will be housed within IMI (9/00) |
| Procyon BioPharma Inc. (Canada; TSE:PBP) | Biovation Ltd. (Scotland) | Agreement/development of chimeric and deimmunized ANA therapeutic monoclonal antibodies | Companies signed a letter of intent for the agreement; the definitive agreement will spell out in greater detail the development plans, milestones, deliverables and contractual obligations (10/00) |
| Progen Industries Ltd. (Australia; PGLAF) | Medigen Biotechnology Corp. (Taiwan) | Development collaboration/Progen s PI-88 for the potential treatment of cancer and cardiovascular disease | MBC will fund and conduct, at no cost to Progen, several trials; MBC will be entitled to receive 15% of Progen s future PI-88 revenues generated from cancer and cardiovascular disease and MBC has the right to negotiate the disease and MBC has of several Phase III clinical trials in the diseases; Progen will supply PI-88, technical expertise and technical know-how to assist MBC in establishing a cGMP-compliant pharmaceutical manufacturing facility in Taiwan (6/00) |
| Proligo LLC | Inex Pharmaceuticals Corp. (Canada; TSE:IEX) | Manufacturing agreement/Proligo will contribute manufacturing, management and marketing services, and Inex will contribute intellectual property and patents; the compounds to be manufactured are phosphorothioatecontaining nucleic acids that are capable of inhibiting production of disease-causing proteins | The two parties will receive a share of revenues based upon their respective contributions (5/00) |
| Prolinx Inc. | CalbiochemNovabiochem Corp. (unit of CN Bio-Sciences Inc.) | Nonexclusive, worldwide, co-label agreement for Prolinx s Versalinx Chemical Affinity Tools product line | Marketing rights granted are limited to research applications in the field of life science; Prolinx retains all rights to intellectual property and licensing for commercial applications for the Versalinx technology (9/00) |
| Protein Design Labs Inc. (PDLI) | Celltech Chiroscience plc (UK; LSE:CTH) | Cross-license agreement/intellectual property in the field of humanized monoclonal antibodies | Celltech will pay a $3M up-front fee for a nonexclusive worldwide license to PDL s antibody humanization patents for up to three Celltech antibodies; PDL will pay Celltech an up-front fee for nonexclusive worldwide rights to Celltech s antibody humanization patent for up to three PDL antibodies; upon exercise of a license for a particular antibody, the licensee will pay an additional fee; each company will pay royalties to the other based on sales of licensed antibodies (1/00) |
| Protein Design Labs Inc. (PDLI) | Tanox Inc. (TNOX) | License/use of PDL s humanization technology for monoclonal antibodies | Tanox will pay a $2.5M up-front fee for rights to obtain a nonexclusive license for up to four Tanox antibodies; up-front payment was based on PDL s $4M standard fee, less a credit of $1.5M for a fee paid previously for an antibody, which has been incorporated into the new agreement; upon exercise of a license for a particular antibody, Tanox will pay an additional fee, annual maintenance fees and royalties on sales (4/00) |
| Protein Design Labs Inc. (PDLI) | InterMune Pharmaceuticals Inc. (ITMN) | Collaboration/PDL will humanize a monoclonal antibody targeted to Pseudomonas aeruginosa | PDL will receive an up-front fee and will be entitled to milestone payments, as well as annual maintenance payments and royalties (11/00) |
| Protein Pathways Inc. | UroGenesys Inc. | Research collaboration/application of Protein Pathways bioinformatics technologies to UroGenesys database of cancer antigens | Companies expect the combination of technologies to uncover functional information that will guide development of UroGenesys antigens, as well as identify new candidates for cancer therapy (2/00) |
| Protein Sciences Corp. | HTS Biosystems | Discovery collaboration/develop novel protein mole cules for the drug and diag nostics markets | PSC granted HTS exclusive rights to its protein library, and retained the right to sell all bulk proteins and peptides and affinity molecules (11/00) |
| Proteome Inc. | DoubleTwist Inc. | Database agreement/provide data from Proteome s BioKnowledge Library through the genomic research portal DoubleTwist.com | DoubleTwist will integrate three model organism database volumes of the BioKnowledge Library; Proteome and DoubleTwist will share revenues generated by sales of information based on Proteome s contribution to the portal (6/00) |
| Proteome Inc. | Celera Genomics (NYSE:CRA) | Strategic collaboration to link Proteome s BioKnowledge library through the Celera Discovery System | Proteome will license the BioKnowledge Library to Celera for distribution with the Celera Discovery System (9/00) |
| Proteome Systems Ltd. (Australia) | Sigma-Aldrich (SIAL) | Manufacturing and exclusive distribution agreement | Sigma-Aldrich will exclusively manufacture and distribute certain products developed by Proteome Systems for use in proteomic analysis (10/00) |
| Qiagen NV (the Netherlands; QGENF) | Luminex Corp. (LMNX) | Strategic alliance/develop range of consumable kits and assays | The companies will develop the kits and assays using Luminex s LabMAP technology; Luminex received an up-front payment and will receive future royalty payments (11/00) |
| Quantum. Dot Corp. | Genentech Inc. (NYSE:DNA) | Evaluation/Genentech will evaluate for use in assays Quantum Dot s Qdot Nanocrystal technology, which consists of molecule-size semiconductors that light up like LEDs and enable sensitive detection of DNA and proteins | Genentech joins Quantum Dot s Technology Access Program as a charter member; during 2000, Qdot Nanocrystals will be available only to participants in the access program and to select academic centers of excellence (4/00) |
| Regeneron Pharmaceuticals Inc. (REGN) | Shearwater Corp. | Agreement/PEGylation of the obesity drug Axokine | Shearwater will use its PEGylation technology to develop a PEGylated form of Axokine in exchange for license fees, royalties and exclusive rights to supply the PEG (polyethylene glycol) reagent (12/00) |
| Response Genetics Inc. | Dianon Systems Inc. | Sales and distribution agreement/Danenberg Tumor Profile chemotherapy guidance system | Exlusive third-party U.S. sales and distribution; Dianon made an equity investment in Response of $1M (11/00) |
| Ribozyme Pharmaceuticals Inc. (RZYM) | Elan Corp. plc (Ireland; NYSE:ELN) | Joint venture/RPI s Herzyme ribozyme against human epidermal growth factor receptor-2 (HER-2) for treatment of breast and other cancers using Elan s Medipad drug delivery system | Under terms of transaction (preliminary announcement made 12/99), companies created a joint venture called Medizyme Pharmaceuticals Ltd. to develop and commercialize the product, licensed from RPI, which has contributed $12M in initial funding in exchange for 80.1% of Medizyme s capital stock; Medizyme will receive additional funding from RPI s sale of Elan of convertible preferred stock; Medizyme paid RPI a license fee; Elan purchased $5M of RPI common stock and will purchase another $5M in 15 months as a mile stone payment; Elan also received warrants to purchase common stock and has the right to exchange its RPI preferred stock for additional Medizyme capital stock or RPI common stock (1/00) |
| Rigel Pharmaceuticals Inc. (RIGL) | Cytomation Inc. | Collaboration/screening for new drugs and targets | Companies will pair Cytomation s ultra-highspeed live-cell analyzer and sorter with Rigel s retroviral and gene transfer techniques to screen molecules for new drugs and drug targets (9/00) |
| Rigel Pharmaceuticals Inc. (RIGL) | Questcor Pharmaceuticals Inc. (AMEX:QSC) | Agreement to sell exclusive rights to certain of Questcor s antiviral drug research technology | Rigel receives certain antiviral technology, including the hepatitis C drug discovery technology, in exchange for a cash payment, a payment of Rigel stock, and future milestone and royalty payments (9/00) |
| Rosetta Inpharmatics Inc. (RSTA) | Abbott Laboratories (NYSE:ABT) | Agreement/investigation of molecular basis of toxicity of compounds in animal and human liver model systems | Each company will fund its efforts; collaboration will use the FlexJet DNA microarray platform, the Resolver Expression Data Analysis product and Abbott s toxicological science expertise (11/00) |
| Rosetta Inpharmatics Inc. (RSTA) | Gemini Genomics plc (GMNI) | Discovery partnership/identification and characterization of sets of genes associated with common human disease | Initial research will focus on the analysis of RNA collected from Gemini s clinical populations; each company will fund its respective contributions and will jointly own intellectual property; they intend to commercialize the rights by licensing them to third parties (11/00) |
| RxKinetix Inc. | Elan Corp. plc (Ireland; NYSE:ELN) | Joint venture/development of compound formulations for the treatment of oral mucositis | Initial terms of the agreement call for a three-year, extendible research and development program; each company is contributing technology; Elan will make a $2.5M equity investment in RxKinetix; the R&D program will be jointly funded; Elan will also subscribe to a convertible note (5/00) |
| Sangamo BioSciences Inc. (SGMO) | Rosetta Inpharmatics Inc. (RSTA) | Joint research collaboration | The companies intend to apply their technologies in gene regulation and informational genomics to perform functional genomic studies on potential therapeutic targets; each company will fund its respective efforts (9/00) |
| Sangamo BioSciences Inc. (SGMO) | Exelixis Inc. (EXEL) and Artemis Pharmaceuticals GmbH (Germany) | Production of knockout mice for functional gene validation | Collaboration will combine the companies technologies (10/00) |
| Scriptgen Pharmaceuticals Inc. (now Rigel Inc.) | 3-Dimensional Pharmaceuticals Inc. | Settlement of intellectual property dispute/Scriptgen s ATLAS (Any Target Ligand Affinity Screen) and 3DP s ThermoFluor assay technology | 3DP will purchase a limited nonexclusive worldwide license to current and pending patents related to Scriptgen s ATLAS; 3DP will grant Scriptgen a limited, nonexclusive worldwide license to pending patents relating to ThermoFluor; both companies can use their assay technologies for identification of drugs in a broad range of therapeutic areas, with the exception of anti-infectives, in which Scriptgen holds a preferential position (3/00) |
| Seattle Genetics Inc. | ICOS Corp. (ICOS) | Development and manufacturing/provide qualified, GMP-grade product for clinical testing | ICOS will provide the product, a monoclonal antibody for cancer therapy; Seattle Genetics retains the rights to commercialize the product; terms were ND (11/00) |
| Select Therapeutics Inc. (OTC BB:SLPU) | Cytomatrix LLC | Joint venture formation/Cell Science Therapeutics | Cell Science will develop and commercialize novel biopharmaceutical products based on technologies in cell culture, tissue engineering and immunotherapy; the joint venture encompasses all of Cytomatrix s assets and Select s vaccine program (12/00) |
| Sentron Medical Inc. | Genzyme Tissue Repair (GZTR) | License/use of Sentron s autologous chondrocyte graft technology to grow preformed cartilage tissue on a twodimensional surface | Genzyme gains an exclusive worldwide license and related intellectual property rights and will provide Sentron up-front and milestone payments, the most significant of which are tied to commercialization of the technology; payment will be made either in equity in Genzyme Tissue Repair or a combination of equity and cash; Genzyme also will pay royalties (4/00) |
| Sequenom Inc. (SQNM) | Methexis Genomics NV (Belgium) | Equipment purchase, research collaboration/companies will use combined technologies to discover and assess genetic variations relevant to both medical and agricultural applications | Methexis purchased Sequenom s MassARRAY system for differential sequencing to discover genetic variations; financial details of the collaboration were ND (3/00) |
| Sequenom Inc. (SQNM) | Genaissance Pharmaceuticals Inc. (GNSC) | Technology collaboration/use of Sequenom s MassARRAY system as the platform for Genaissance s high-throughput haplotyping facility | Agreement follows an initial MassARRAY system placement at Genaissance, which will now purchase at least two additional units; Sequenom will develop assays for Genaissance s HAP markers (5/00) |
| Sequenom Inc. (SQNM) | Metabion GmbH (Germany) | Technology sale and supply agreement/Sequenom s MassARRAY technology | Metabion will use Sequenom s MassARRAY technology to monitor the quality of Metabion s high-volume oligonucleotide production while providing Sequenom with a reliable and consistent source for oligonucleotides (6/00) |
| Sequitur Inc. | Vertex Pharmaceuticals Inc. (VRTX) | Licensing agreement for antisense functional genomics technology | Vertex will provide financial support for collaborative research to be performed at Sequitur, and Vertex will pay licensing fees (9/00) |
| Shaman Pharmaceuticals Inc. (OTC BB: SHMN) | Metabolex Inc. | License agreement/Shaman s diabetes drug discovery program, principally focused on orally available plant-derived compounds for Type II diabetes; includes library of more than 300 compounds and extracts | Metabolex acquired materials and exclusive licenses to Shaman s diabetes drug discovery program for use within specific territories; Shaman retains all rights to lead diabetes compound, Masaprocol (1/00) |
| Shearwater Polymers Inc. | Sensus Drug Development Corp. | License/use of Shearwater s polyethylene glycol technology (PEGylation) to develop an improved formulation of Sensus Somavert, a genetically modified form of human growth hormone | Shearwater will receive substantial up-front payments, rights to manufacture the polyethylene glycol formulation and a share of downstream revenues (4/00) |
| SIGA Technologies Inc. (SIGA) | New England Biolabs | Research collaboration/combines SIGA s vaccine delivery technology with schistosomiasis antigens identified by NEB scientists | Research will be carried out at SIGA Research Labs, the biotechnology division of SIGA, and at NEB; companies also announced successful outcome of a joint research project using SIGA s vaccine delivery technology for the expression of self-cleaving programs called inteins (3/00) |
| SIGA Technologies Inc. (SIGA) | Maxygen Inc. (MAXY) | Research collaboration/the development of novel vaccines | Collaboration will combine SIGA s vaccine delivery system with Maxygen s antigens for generating an immune response (10/00) |
| SignalGene Inc. (Canada; TSE:SGI) | CroMedica Prime Inc. | Service agreement for genotyping services | SignalGene will use its pharmacogenomics platform for the genotyping of drugs metabolizing enzymes on samples collected by CroMedica Prime from clinical trial participants (10/00) |
| SkyePharma plc (UK; SKYE) | Amgen Inc. (AMGN) | Evaluation/use of SkyePharma s DepoFoam sustained-release injectable delivery system with an undisclosed Amgen product | Upon signing the contract, SkyePharma made a final contingent payment to former shareholders in DepoTech, which SkyePharma acquired 3/99; each shareholder will receive an additional 0.79 SkyePharma American Depositary Shares for every 10 shares of DepoTech owned; shares are worth 13.3M (US$21.3M) at the 3/31/00 closing price (4/00) |
| Structural Bioinformatics Inc. | De Novo Pharmaceuticals Ltd. (UK) | Access agreement/multiple therapeutic target classes within SBI s ProMax 3-dimensional protein structure database | Financial terms were ND (11/00) |
| Symyx Technologies Inc. (SMMX) | PE Biosystems (NYSE:PEB) | Development collaboration/development of Symyx s polymer synthesis materials and methods for use in DNA analysis | Companies will jointly design polymers, as well as methods and instrumentation for screening those polymers; Symyx will make and screen the polymers for use in nucleic acid separations; PE will develop and commercialize products; under the two-year agreement, Symyx will receive payments for development funding and late-stage royalties on resulting products; in addition, Symyx will receive a payment for transfer of existing development compounds (1/00) |
| Synergy Pharmaceuticals Inc. | United Therapeutics Corp. (UTHR) | License, acquisition option/rights to antiviral drug compounds designed to prevent three-dimensional folding of all viruses (including hepatitis B and C, dengue and Japanese encephalitis) that bud from the endoplasmic reticulum within cells | United Therapeutics licensed the compounds and purchased 15% of Synergy, with an option to acquire the remainder of the company (3/00) |
| Syrrx Inc. | MolSoft LLC | Strategic alliance/accelerate structure-guided drug discovery | Companies will combine MolSoft s Virtual Lig and Screening technology with Syrrx s highthroughput structural proteomics platform for 10year deal (10/00) |
| Targeted Genetics Corp. (TGEN) | Biogen Inc. (BGEN) | Definitive agreement/establishment of a major multiproduct development and commercialization collaboration | The collaboration will replace and expand an agreement Biogen established in 1995 with Genovo, a privately held company to be acquired by Targeted Genetics; Targeted Genetics will work on the development of up to four new gene therapy products for Biogen; in return for access to technologies and product development capabilities, Biogen will pay $8M in up-front payments, as well as ongoing research and development funding and milestone payments; the funding also includes a $10M line of credit to Targeted Genetics and a future $10M equity investment; total value could be $125M, not including manufacturing and royalty payments (8/00) |
| Techniclone Corp. (now Peregrine Pharmaceuticals Inc.; PPHM) | SuperGen Inc. (SUPG) | License agreement/use of Techniclone s Vascular Targeting Agent to develop cancer therapeutics | Techniclone will receive an up-front payment, milestones and royalties on products that emerge (1/00) |
| Techniclone Corp. (now Peregrine Pharmaceuticals Inc.; PPHM) | Oxigene Inc. (OXGN) | Joint venture/development of cancer therapeutics combining Techniclone s vascular targeting agents and Oxigene s tubulinbinding compounds | Techniclone will receive an up-front licensing fee and milestone payment; Oxigene will fund development expenses, and the companies will share royalties and certain fees generated by the joint venture; Techniclone will supply its intellectual property and the expertise of VTA s inventor, along with the most promising lead candidates (3/00) |
| Techniclone Corp. (now Peregrine Pharmaceuticals Inc.; PPHM) | Scotia Pharmaceuticals Ltd. (UK; LSE:SOH) | License/use of Techniclone s Vascular Targeting Agent technology in photodynamic therapy applications | Companies signed a binding letter of intent for exclusive worldwide rights; Techniclone will receive a licensing fee, milestone payments and royalties on sales (4/00) |
| Techniclone Corp. (now Peregrine Pharmaceuticals Inc.; PPHM) | Oxigene Inc. (OXGN) | Joint venture/development of vascular targeting technologies | Oxigene will spend up to $20M to fund development expenses at the venture, Arcus Therapeutics LLC; subsequent costs will be split equally; in addition, Oxigene paid a $1M up-front licensing fee and will purchase $2M of Techniclone s common stock at the current market price; Oxigene will also pay another $1M in cash and buy $1M in Techniclone stock upon filing of an IND for the first clinical candidate; Arcus plans to sublicense the technology to other companies for non-conflicting applications; Techniclone will receive 75% of such income until it receives $10M; thereafter, licensing fees will be shared 50-50; the companies will share any royalties or profits equally (5/00) |
| Techniclone Corp. (now Peregrine Pharmaceuticals Inc.; PPHM) | Scotia Pharmaceuticals Ltd. (UK; LSE:SOH) | License/segment of Techniclone s Vascular Targeting Agent technology, specifically related to applications of photodynamic therapy | Techniclone will receive a licensing fee, milestones (as much as $7M) and royalties upon commercialization (8/00) |
| Texas Biotechnology Corp. (AMEX:TXB) | ICOS Corp. (ICOS) | Joint venture/development of Texas Biotech s endothelin A receptor antagonists, such as sitaxsentan, which is nearing a Phase IIb/III trial in pulmonary hypertension | Both companies will equally fund the cost of research and development of sitaxsentan in chronic heart failure, and explore applications for secondgeneration endothelin antagonist compounds, commercialize resulting products and share equally in the profits worldwide; ICOS will make milestone payments to Texas Biotechnology that could be as much as $55.5M for the development and commercialization of products resulting from the collaboration (6/00) |
| Third Wave Technologies Inc. | Specialty Laboratories | Development collaboration/development of new applications for Third Wave s proprietary Invader technology platform | ND (7/00) |
| Third Wave Technologies Inc. | Epoch Biosciences Inc. (EBIO) | Development, licensing and supply agreement | Epoch will develop, license and supply certain of its technologies for Third Wave s Invader operating system for genetic analysis; Epoch will provide access to fluorescent dye chemistries and will receive licensing payments and royalties on sales; Third Wave will fund certain development activities and will have the option to license Epoch s minor groove binder and modified base technologies (10/00) |
| Tolerance Therapeutics LLC | Repligen Corp. (RGEN) | Acquisition of patent rights/use of CTLA4-Ig, a derivative of a natural immune cell protein capable of blocking immune responses, in immune-based diseases and organ transplantation | ND (5/00) |
| Transgene SA (France; TRGNY) | IntroGene BV (the Netherlands) | License agreement/collabora tion in the field of complementation cell lines for commercial production of adenoviral vectors | Agreement provides for nonexclusive crosslicensing of certain intellectual property rights and for the joint development and marketing of a new generation of IntroGene s proprietary PER.C6 cell line (6/00) |
| Transgene SA (France; TRGNY) | Mirus | Research and license agreement to develop gene therapy products | Companies will use Mirus muscle delivery technology to deliver Transgene s plasmid-based and adenoviral vectors to skeletal muscle; Transgene will fund a one-year research program and Mirus grants Transgene an option to license its technology over a five-year period (10/00) |
| TranXenoGen Inc. | US Transgenics Inc. | Joint venture and research collaboration/development of recombinant human serum albumin (HAS) under JV structure and research collaboration to develop other proteins in the albumin fraction of chicken eggs using TranXenoGen s transgenic chicken technology | TranXenoGene will house initial HSA project at its facilities; US Transgenics will provide protein chemistry technology and access to product markets (1/00) |
| Trega Biosciences Inc. (TRGA) | Evotec Biosystems AG (Germany; Neuer Markt:EVT) | License agreement, research collaboration and purchase agreement/development of high-throughput ADME (absorption, distribution, metabolism and excretion) assays for use in drug discovery lead optimization; license of Trega s IDEA predictive model; purchase of Trega s Chem.Folio chemistry libraries | Evotec receives exclusive license to all developed ADME assays, while Trega will be entitled to royalties on drug discovery collaboration revenues of assays offered to third parties by Evotec; Trega also will own the data generated on a selected set of compounds; Evotec gains a license to IDEA; Chem.Folio library compounds will be screened through the new assays and the data will be used to enhance IDEA; Evotec will purchase certain amounts of all compounds in Trega s Chem.Folio library, and will receive associated information; Evotec will use the compounds for internal drug discovery and make them accessible to screening customers for a fee that includes a payment to Trega (1/00) |
| Trega Biosciences Inc. (TRGA) | Discovery Technologies Inc. (unit of Discovery Partners International Inc.) | Technology alliance/use of Trega s Chem.Folio chemistry libraries by Discovery for client screening using an ultra-high-throughput screening system | Trega receives an up-front payment plus additional fees on compounds accessed by Discovery customers for a period of two years; Discovery s use of the libraries is nonexclusive (2/00) |
| Trega Biosciences Inc. (TRGA) | GemStone Systems Inc. | Licensing agreement for the GemStone/J e-business software | GemStone licensed its software to Trega for use in the web-based version of the iDEA predictive model for absorption (9/00) |
| Trega Biosciences Inc. (TRGA) | PhycoGen Inc. | Service agreement for Chem.Folio chemistry | Trega will provide its Chem.Folio chemistry services for PhycoGen s use in discovery programs that involve biological cell adhesion processes; Trega will receive up-front and milestone payments (10/00) |
| Trega Biosciences Inc. (TRGA) | Tibotec Group N.V. (Belgium) | License/Trega s iDEA Predictive ADME Simulation System for absorption | Tibotec will use the module in its drug discovery activities, which are focused in the area of HIV and AIDS (12/00) |
| Tripos Inc. (TRPS) | Lion Bioscience AG (Germany; LEON) | Research collaboration/integration of Lion s bioinformatics and Tripos chemoinformatics expertise to develop a unified platform | Companies formalized alliance that has grown out of 18 months of unannounced collaborative efforts; Lion agreed to purchase 409,091 shares of convertible preferred stock from Tripos for $22 per share, or $9M, giving Lion an 11% stake in Tripos (2/00) |
| United Therapeutics Corp. (UTHR) | Nova-Tex Ltd. | Distribution agreement/United Therapeutics subcutaneous prostacyclin therapy, Uniprost | Strategic alliance for the distribution of Uniprost in Israel (6/00) |
| UroCor Inc. (UCOR) | Immunex Corp. (IMNX) | License agreement/UroCor s cancer-derived antigens | Immunex will pay an initial license fee, plus potential milestone and royalties, and will be responsible for all R&D and potential commercialization costs of any approved therapeutic antibodies against licensed UroCor target antigens (7/00) |
| UroGene SA (France) | SynerGenomics Inc. (Canada) | Research collaboration/identification of genes associated with the contraction and progression of prostate cancer | The two-year agreement calls for the two sides to conduct genetic studies of six key chromosomal regions discovered by UroGene; UroGene will retain exclusive ownership of all commercial applications of the genes discovered and SynerGenomics will receive service fees, as well as milestone payments (11/00**) |
| UroGenesys Inc. | Genentech Inc. (NYSE:DNA) | License/development of antibody-based therapeutics for cancer using UroGenesys Prostate Stem Cell Antigen (PSCA) as a target antigen | The license covers patent rights to PSCA as a target for antibody therapy in any cancer indication, as well as a panel of monoclonal antibodies; UroGenesys could receive milestone and other payments totaling $33M, in addition to royalties on product sales (7/00) |
| Valentis Inc. (VLTS) | Eurogene Ltd. (UK) | Development collaboration/nitric oxide synthase gene medicine for the prevention or treatment of restenosis following bypass graft surgery | Valentis and Eurogene will share research and development costs and potential revenues (8/00) |
| Valentis Inc. (VLTS) | Heska Corp. (HSKA) | Licensing agreement/gene delivery and DNA manufacturing technology | Heska will use the technology to complete development of a gene medicine to treat canine cancer; agreement includes up-front license fee, milestone payments and a royalty (10/00) |
| Valentis Inc. (VLTS) | Oxford BioMedica plc (UK) | Collaboration/development of a new version of the cancer drug MetXia | The new version will be developed by adding polyethylene glycol chains to the drug using PolyMASC Pharmaceuticals plc s viraMASC PEGylation technology; PolyMASC is a unit of Valentis (12/00) |
| Variagenics Inc. (VGNX) | Waters Corp. (NYSE:WAT) | Development and commercialization agreement/NuCleave genetic variance reagent kits for use in the clinical development of pharmaceuticals | Variagenics will receive $10.5M in equity and technology transfer payments, and up to $4M in milestone payments; Waters will pay royalties on NuCleave reagent kit net sales (6/00) |
| V.I. Technologies Inc. (VITX) | Amersham Pharmacia Biotech (UK; owned by Nycomed; NYSE:NYE; and Pharmacia Corp.; NYSE:PHA); | Marketing and distribution agreement/V.I. s Inactine pathogen inactivation technology for manufacturers of biopharmaceuticals and transgenic products and to plasma fractionators | AP Biotech will exclusively market and distribute the technology in the covered areas; V.I. receives an up-front cash payment, with the potential to receive considerably more in milestone payments and research support, as well as ongoing royalties on sales and use of the technology by AP Biotech customers; companies also will collaborate on development and refinement of the technology; V.I. retains all rights to use Inactine for viral inactivation in blood components such as red cells, platelets and plasma (4/00) |
| Vical Inc. (VICL) | Vascular Genetics Inc. | License agreement/use of Vical s naked DNA delivery technology for VGI s vascular endothelial growth factor-2 (in clinical trials for cardiovascular disorders) | VGI receives an exclusive, royalty-bearing license; in exchange, Vical receives a minority equity interest in VGI (2/00) |
| Vion Pharmaceuticals Inc. (VION) | Achillion Pharmaceuticals Inc. | License agreement/Vion s nucleoside analogue B-LFd4C for treating hepatitis B virus infection and HIV | Achillion will fund development, in return for providing Vion with milestones, downstream royalties and an equity position (2/00) |
| Viragen Inc. (AMEX:VRA) | CryoLife Inc. (NYSE:CRY) | Research collaboration/use of CryoLife s light activation technology with Viragen anticancer proteins delivered to tumors by monoclonal antibodies; the proteins are designed to be activated and separated from the antibodies upon application of light | Companies signed a feasibility agreement (3/00) |
| Viragen Inc. (AMEX:VRA) | Zonagen Inc. (ZONA) | Supply agreement for purpose of a study for genital herpes | Viragen agreed to supply Omniferon to Zonagen to study a topically applied enhanced for mulation of natural alpha interferon for the treatment of genital herpes (8/00) |
| Viragen Inc. (AMEX:VRA) | PolyMASC Pharmaceuticals plc (unit of Valentis Inc.; VLTS) | Collaboration to develop a new treatment for hepatitis C | Companies will use PolyMASC s protoMASC PEGylation process to deliver Viragen s lead drug, Omniferon; financial terms were ND (9/00) |
| Vysis Inc. (VYSI) | Genentech Inc. (NYSE:DNA) | Development and marketing collaboration/use of Vysis PathyVysion HER2 test kit in assessing patients for whom Genentech s Herceptin is being considered; test uses fluorescence in situ hybridization to detect HER2 | Companies will make a coordinated FDA submission and collaboration may extend to future clinical studies (5/00) |
| Waratah Pharmaceuticals Inc. (Canada; CDNX:WAR) | Research Corp. Technologies | License agreement/use of RCT s protein expression to produce Waratah s therapeutic system proteins | Waratah will pay RCT royalties on net sales, including minimum annual royalties; terms were ND (10/00) |
| Xenogen Corp. | Cubist Pharmaceuticals Inc. (CBST) | Evaluation licensing agreement | Agreement provides Cubist with access to Xenogen s real-time, in vivo imaging technolologies (8/00) |
| Xenogenics Corp. (unit of MultiCell Associates Inc.) | Exten Industries Inc. | Supply agreement/MultiCell will supply Exten a unique engineered porcine liver cell line and optimize the interface between this cell line and Exten s SybiolR, a bioartificial liver | ND (3/00) |
| Xenometrix Inc. (OTC BB:XENO) | Genometrix Inc. | License agreement/Xenometrix s collection of geneexpression profiles utilizing all platforms, including microarrays | Genometrix receives a nonexclusive license (3/00) |
| Xoma Ltd. (XOMA) | Allergan Inc. (NYSE:AGN) | Expansion of 6/99 development collaboration/all ophthalmic anti-infective formulations, including stand-alone formulations, of Xoma s recombinant bactericidal/permeabilityincreasing protein | Previous $11M agreement included antibiotics combinations to treat bacterial eye infections; amended agreement calls for additional milestones (5/00) |
| Xoma Ltd. (XOMA) | Celltech Therapeutics Ltd. (unit of Celltech plc; UK; LSE:CTP) | License/use of Xoma s bacterial cell expression systems for pharmaceutical production | Celltech gains a nonexclusive license to the technology; Xoma s license terms typically include up-front fees, milestone payments and royalties on sales; Celltech agreement is a cross-license that allows Xoma to use Celltech s expression technologies and settles all patent opposition proceedings between the companies (5/00) |
| Xoma Ltd. (XOMA) | ZymoGenetics Inc. | License/use of Xoma s bacterial expression systems for pharmaceutical cell production | ZymoGenetics gains a nonexclusive license to the technology; Xoma s license terms typically include up-front fees, milestone payments and royalties on sales (6/00) |
| Xoma Ltd. (XOMA) | Allergan Inc. | Dissolved deal/bactericidal permeability-increasing protein (BPI) | Allergan chose to give back all rights to ophthalmic anti-infective products containing BPI (11/00) |
| XTL Biopharmaceuticals Ltd. (Israel) | Hybrigenics SA (France) | Agreement to co-develop drugs against hepatitis C virus | Agreement combines Hybrigenics functional proteomics and bioinformatics drug discovery integrated platform with XTL s in vitro and in vivo predictive models of human HCV; firms will share in research and development costs; each party will retain an equal interest in products developed and will jointly fund development through Phase II trials; Hybrigenics also granted XTL a nonexclusive license to HCV PIMRider technology database (9/00) |
| Zyomyx Inc. | Fujirebio Inc. (Japan) | Collaboration and license/develop protein biochips | Zyomyx will receive funding to support research and development efforts for three years, as well as royalty payments on future sales; Fujirebio receives exclusive commercialization rights in Japan (11/00) |
| Zyomyx Inc. | Cambridge Antibody Technology plc (UK; LSE:CAT) | Development collaboration/high-density protein biochips based on antibody arrays | Companies will jointly develop arrays to detect proteins from complex biological mixtures; finan cial terms were ND (12/00) |
| Notes: This chart does not cover agreements between biotech companies or agricultural agreements. It covers the time between 1/1/00 and 12/31/00; stocks trade on NASDAQ unless otherwise noted. AMEX = American Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over The Counter Bulletin Board; TSE = Toronto Stock Exchange; VSE = Vancouver Stock Exchange. ND = Not disclosed, reported and/or available ** Denotes the date the item ran in BioWorld International | |||
To read more on related topics, click on one of the words below.